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Vitamin D is crucial for calcium and phosphorous homeostasis and for bone health. 
Evidence also has linked vitamin D deficiency with impaired immune function. Studies 
conducted in populations that reside close to the equator show that vitamin D 
insufficiency is prevalent despite abundant UVB. Response to oral vitamin D 
supplementation in this population is not known. The aim of this study was to determine 
effect of vitamin D supplementation on maternal and infant plasma 25(OH)D 
concentrations, and on markers of bone turnover, infant growth, gross motor development 
and morbidity. A randomized, placebo-controlled, double-blind trial (NCT02210884) 
was conducted in Sidama Zone (7oN, 38oE), Southern Ethiopia. Lactating women 
(n=126) enrolled within two weeks postpartum were randomized to vitamin D3 (15,000 
IU/week) or placebo for 12 months. Plasma 25(OH)D, bone-specific alkaline phosphatase 
(BAP), osteocalcin (OC) and C-telopeptide for type 1 collagen (CTX) were determined. 
Skin reflectance, dietary intake, and individual UVB exposure were also measured. 
Moreover, infant health and growth outcomes were also assessed. Median (IQR) 
25(OH)D concentrations were not significantly different between vitamin D and control 
groups at baseline [45 (39, 56) nmol/L vs 47 (37, 57) nmol/L, p = 0.697]. 25(OH)D 
concentrations were significantly higher in the vitamin D group at end-line [109 (93, 121) 
nmol/L vs 63 (49, 81) nmol/L p < 0.0001]. All women in the vitamin D group were 
vitamin D sufficient (> 50 nmol/L) by the end of the study. Furthermore, 95% had 
attained 25(OH)D concentrations > 75 nmol/L compared to 39% in the control group. 
End-line infant 25(OH)D concentrations were not significantly different between groups. 
Maternal BAP and OC concentrations significantly increased from two weeks post-
partum to end-line in both groups ( p < 0.001). No significant differences by treatment 
were seen for all bone turnover markers, infant growth, and health outcomes ( p = 0.974) . 
Weekly vitamin D supplementation safely eliminated vitamin D insufficiency in the 
study population. Our results suggest that supplementation can be used to improve 
vitamin D status in populations with limited sun exposure and low dietary vitamin D and 
calcium intake.Intervention did not affect bone turnover and infant health outcomes.  
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CHAPTER I 
 
 
INTRODUCTION 
BACKGROUND  
Vitamin D, commonly referred to as the sunshine vitamin, is a pro-hormone that 
performs critical functions in the body1,2. Vitamin D can be produced in the skin by the action of 
ultraviolet light (UVB) and can also be obtained from a few foods in the diet3. The biologically 
active metabolite of vitamin D, calcitriol, acts as a ligand for the vitamin D receptor (VDR) which 
in turn regulates gene transcription and signal transduction pathways in target cells2. The widely 
established physiological function of vitamin D is the regulation of calcium and phosphorous 
homeostasis1,2. Through regulation of these nutrients vitamin D ensures proper mineralization of 
bone2. Furthermore, the VDR has been discovered in cells that perform functions beyond calcium 
homeostasis4. Vitamin D influences differentiation and intracellular calcium handling in muscle 
cell5. It also contributes to the regulation of differentiation and proliferation of cells including β 
cells of the pancreas and hematopoietic cells2,4. The VDR is found in activated T-cells, 
macrophages, monocytes and cytotoxic T cells and modulates immune response2,6. Recent 
evidence also has linked vitamin D with type 1 diabetes, breast and colon cancer, rheumatoid 
arthritis, infectious diseases and cardiovascular diseases7-9.  
Vitamin D status is defined using plasma or serum level of 25-hydroxyvitamin D 
(25(OH)D) as a biomarker10. According to the cutoff set by the Institute of Medicine (IOM) to  
2 
 
define vitamin D deficiency11, 25(OH)D concentration less than 30 nmol/L are indicative of 
deficiency that can result in rickets and osteomalacia. Vitamin D status is considered inadequate 
for bone and overall health when levels are in the 30-50 nmol/L range. A concentration above 50 
nmol/L indicates adequacy11.  
Vitamin D deficiency results in rickets in children and osteomalacia in adults1,12. Rickets 
is a manifestation of chronic vitamin D deficiency and commonly presents in children between 
the ages of 6 and 29 months13,14. Children with rickets suffer from growth retardation and skeletal 
deformities12,14. Sub-clinical vitamin D deficiency in children causes hypocalcemia and bone 
demineralization and can present as hypocalcemic seizures in infants14. Vitamin D deficiency in 
adults has been associated with muscle weakness, osteoporosis, and increased fracture risk15,16.  
Meeting vitamin D needs is especially important during pregnancy and lactation due to 
increased demands to support fetal and infant growth and development17,18. Stores of vitamin D 
acquired in utero, and breast milk are the main sources of vitamin D for infants19. Maternal 
vitamin D and 25(OH)D are not readily transferred into breast milk which has been shown to be 
low in vitamin D19,20. Maternal vitamin D deficiency, exclusive breastfeeding, darker skin 
pigmentation and limited sun exposure are associated with rickets in infants18. 
Several factors can affect cutaneous synthesis, which is the major source of the vitamin in 
parts of the world where foods are not fortified with vitamin D21,22. Skin pigmentation determines 
the amount of light that penetrates the skin to produce vitamin D23. Individuals with darker skin 
have a higher level of melanin which acts as a UV filter and are thus at a higher risk of vitamin D 
deficiency especially if sun exposure is limited3,24. Latitude affects the amounts of UVB rays that 
reach the surface of the skin1. Regions located between 37º N and 37º S have sufficient sunlight 
to maintain optimal concentrations of 25(OH)D throughout the year21. However, since other 
factors such as season, dress habits, sunscreen use and air pollution influence vitamin D 
synthesis, deficiency and insufficiency is prevalent in these regions. Hypovitaminosis D has been 
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reported in India25, Iran26 and Turkey27 among pregnant women and newborns and in the United 
Arab Emirates (UAE) among exclusively breastfed infants and lactating mothers28. Vitamin D 
deficiency has also been reported in other target groups in sunshine abundant countries29-32. In 
populations with low dietary vitamin D and calcium intake these factors can compromise vitamin 
D status and may contribute to high prevalence of infectious disease and maternal mortality33.  
Ethiopia is located near the equator and has abundant sunshine throughout the year. 
Consequently, vitamin D status and risk factors for deficiency have not been widely explored. 
Two hospital-based case-control studies conducted in the late 1990’s reported a strong association 
between limited sun exposure and rickets34 and a high prevalence of rickets in children with 
pneumonia35. A systematic review identified lack of exposure to sunshine and inadequate intake 
of vitamin D as major risk factors for rickets34. Studies that measured 25(OH)D have reported a 
higher than anticipated vitamin D deficiency (< 30 nmol/L) and insufficiency ( 30-50 nmol/L). In 
1999 Feleke et al. reported a mean 25(OH)D concentration of 23.5 nmol/L for adults and 25 
nmol/L for pregnant women36. In a recent study conducted among children (aged 10-18) 42% had 
25(OH)D concentrations below 50nmol/L37. Furthermore, in an assessment of vitamin D status of 
rural women of reproductive age in southern Ethiopia, 15.8% had 25(OH)D levels below 30 
nmol/L and 69.4% had levels between 30-50 nmol/L38.  
According to the 2016 Ethiopian Demographic and Health Survey, 52% of all children 
under the age of six months are exclusively breastfed and 98% of mothers at least initiate 
breastfeeding of their infants39. Breastfeeding is widely promoted as the best food for the baby for 
the first six months of life. However, lactating women and infants have not been assessed for 
vitamin D status in Ethiopia. The contribution of skin pigmentation, UVB exposure, traditional 
practices that limit sun exposure and other risk factors for vitamin D deficiency also needed to be 
explored. Thus the primary aims of this study were:  
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1) To determine the effects of a weekly vitamin D supplement (15,000 IU) vs. placebo 
administered to lactating women for 12 months on maternal and infant markers of vitamin D 
status.  
2) To determine variability in skin color and personal ultraviolet light (UVB) exposure and their 
association with vitamin D status, among lactating women.  
Secondary outcome measures include maternal markers of bone turnover, infant growth, 
infant gross motor development, infant morbidity. 
 
PRIMARY AND SECONDARY OBJECTIVES  
Primary objectives: 
1. To assess effects of weekly vitamin D supplementation administered to the mothers on 
25(OH)D concentrations of mothers and infants; 
2. To assess the association between skin reflectance (color), dress habits, sun-seeking 
behavior, UVB exposure, and 25(OH)D concentrations.  
Secondary objectives: 
1. To assess the effect of maternal vitamin D supplementation on maternal markers of bone 
turnover; 
2. To compare differences in attainment of infant motor developmental milestones between 
treatment groups; 
3. To compare differences in infant growth between treatment groups;  
4. To compare differences in incidence infant morbidity between treatment groups;  
5. To assess dietary vitamin D and calcium intake among lactating women.  
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HYPOTHESIS  
Null Hypothesis for primary objectives  
HO1: There is no significant difference in maternal 25(OH)D concentration between the vitamin 
D and placebo groups.  
HO2: There is no significant difference in infant 25(OH)D concentration between the vitamin D 
and placebo groups.  
HO3: Skin reflectance, UVB exposure, dress habits and sun-seeking behaviors will not 
significantly predict 25(OH)D concentrations. 
Null Hypothesis for secondary objectives  
HO4: There is no significant difference in parathyroid hormone (PTH) concentrations between 
vitamin D and placebo groups.  
HO5: There is no significant difference in maternal and infant bone specific alkaline phosphatase 
concentrations between vitamin D and placebo groups.  
HO6: There is no significant difference in osteocalcin concentrations between vitamin D and 
placebo groups.  
HO7: There is no significant difference in C-terminal telopeptides of type 1 collagen 
concentrations vitamin D and placebo groups.  
HO8: There is no significant difference in infant date of attainment of gross motor milestones by 
treatment group.  
HO9: There is no significant difference in infant growth by treatment group. 
HO10: There is no significant difference in the incidence of infant morbidity by treatment group. 
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RATIONALE AND SIGNIFICANCE OF STUDY  
 
Vitamin D insufficiency can occur despite the availability of abundant sunlight due to 
several factors, such as skin pigmentation, dress habits, and sun avoidance, that reduce the 
efficiency of vitamin D synthesis in the skin1. Furthermore, low dietary vitamin D intake and 
absence of vitamin D fortified foods increase the risk of vitamin D deficiency in UVB sufficient 
populations3.  
Individuals with a darker skin color have a higher melanin content in their skin. Melanin 
absorbs UVB light which otherwise starts the synthesis of vitamin D in the body. Melanin can 
reduce the capacity of the skin to produce vitamin D by 95 to 99% in dark skinned individuals 
thus increasing the risk of vitamin D deficiency21. A high prevalence of vitamin D deficiency has 
been reported for dark skinned Indians40, Brazilians41, and African Americans42. 
A conservative dressing style that only allows exposure at the head, the neck region and 
hands limits direct sun exposure and significantly reduces vitamin D synthesis. Depending on the 
type and color of clothing worn, UVB absorption can be reduced by 48-99% 43. Conservative 
dress habits and use of a veil for religious reasons have been shown to significantly contribute to 
the occurrence of vitamin D deficiency in sunshine abundant countries27,44. The fact that 
availability of adequate sunshine alone does not always ensure vitamin D adequacy has been 
supported by several studies carried out in countries with abundant sunshine that reported vitamin 
D deficiency and insufficiency26,27,31,36,38,40,41,44-49.  
 In Ethiopia studies that assessed levels of circulating vitamin D (25(OH)D) have reported 
vitamin D deficiency and insufficiency. A preliminary study, conducted in the area where this 
study was conducted, assessed vitamin D status of women of reproductive age (n=202). The 
study participants performed several outdoor activities and thus had substantial sunlight exposure. 
However, despite abundant sunlight exposure, 15.8% of the women were vitamin D deficient, and 
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69.4% were vitamin D insufficient38. Another study reported mean 25(OH)D concentrations 
indicative of severe vitamin D deficiency ( < 25 nmol/L) for adults (n=30) and pregnant women 
(n=31) residing in Addis Ababa36. A study that assessed 25(OH)D levels of lactating women 
(n=108) in Wondo Genet and Arsi Negele reported 39% vitamin D insufficiency49. Study 
participants had modest clothing habits, did not consume vitamin D rich or fortified foods and 
covered their babies and themselves from the sun due to religious and cultural reasons49.  
  A diet low in calcium and high in phosphorus increases predisposition to vitamin D 
deficiency through blood calcium and parathyroid hormone (PTH) related mechanisms that cause 
secondary vitamin D deficiency. Women residing in the study area have been shown to have a 
low calcium and high phytate intake50 which increases their risk of vitamin D deficiency. All 
factors that influence the vitamin D status of women also negatively influence the vitamin D 
status of newborns and infants and increase the risk of vitamin D deficiency in this target group. 
Infants are especially vulnerable to vitamin D deficiency if they depend on breastmilk for vitamin 
D and are not exposed to sunlight or supplemented with vitamin D after birth 19.   
This study addressed the knowledge gap regarding vitamin D status of populations at risk 
of vitamin D deficiency by assessing vitamin D markers in lactating women and infants. 
Quantitative estimates for factors such as skin pigmentation and sunlight exposure that affect 
vitamin D status of the individual also were generated. Furthermore, the effect of maternal 
vitamin D supplementation on maternal and infant vitamin D status and other related outcomes 
were evaluated. 
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ASSUMPTIONS  
Biological samples were transported from Ethiopia to the US packed in dry ice. It was 
assumed that the samples were transported without damage. Length of storage of frozen samples 
was variable due to the different collection time points. It was assumed that analytes are stable 
after long storage.  
LIMITATIONS 
- The primary aim of this study was to detect differences in maternal 25(OH)D concentration 
between the groups based on vitamin D supplementation. Sample size estimations were based 
on this objective. Hence this study had limited power for subgroup analyses or to test infant 
outcome differences.  
- Becasue our study participants were lactating women, we were not able to ask that they 
provide a fasting blood specimen. Thus biomarker analysis was not performed on fasting 
blood samples.  
- Serum C-terminal telopeptides of type 1 collagen (CTX) values can be influenced by time of 
day (diurnal variation). Due to logistical challenges, we were not able to collect all blood 
samples at the same time of day. 
-  Infant blood samples were collected only at end-line. Samples collected at baseline and at an 
interim point would have enabled a more comprehensive depiction of the impact of the 
intervention.  
- This study did not measure bone mineral content (BMC) or bone mineral density (BMD) 
which are stronger indicators of bone health compared to bone turnover markers.  
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
History of Vitamin D  
“Vitamin D” is the name commonly used to refer to the two different forms of the 
vitamin, D2 (ergocalciferol) and D3 (cholecalciferol). D2 is synthesized by plants through the 
irradiation of ergosterol by yeast. D3 is produced in the skin through the UVB conversion of 7-
dehydrocholesterol to pre-vitamin D3, which then isomerizes to D31. Vitamin D was first 
discovered through the work of McCollum and Mellanby 2. Discovery of vitamin D was tied to its 
ability to heal rickets that could not be cured by Vitamin A. McCollum performed an experiment 
in which he removed vitamin A in cod liver oil to determine if it caused rickets. When cod liver 
oil that did not contain vitamin A cured rickets, he named the unknown vitamin factor vitamin D2. 
Mellanyby hypothesized that rickets was due to a deficiency in the diet. He fed dogs that were 
kept indoors oatmeal to test this hypothesis. When the dogs developed rickets, he then fed them 
cod liver oil and treated rickets. He identified the unknown nutrient in cod liver oil as being able 
to cure rickets2.   
Food Sources and Forms  
Vitamin D is naturally found in very limited food sources 15. Fatty fish, fish liver oil, egg 
yolk and sun-dried mushrooms are the main foods that contain vitamin D 11. Non-endogenous 
vitamin 
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D can be either in the form of D3 or D2. D3 is obtained from animal sources and D2 is mainly 
obtained from plant sources or dietary supplements 1. In the US and Canada milk and other foods 
such as margarine, yogurt, ready-to-eat cereal, and orange juice are fortified with vitamin D. Also 
vitamin D supplements are widely available1. However, in most countries in Europe, Asia, and 
Africa's foods are not fortified with vitamin D 51. There has been debate over whether what form 
of vitamin D, D2 or D3, is more metabolically active. Although some researchers have argued that 
D2 is more potent, a recent meta- analysis reported that a high dose of vitamin D3 raises 25(OH) 
D proportional to that of vitamin D2 52. Breast milk is a poor source of vitamin D. How much 
vitamin D is in breast milk will depend on vitamin D status of mothers. Breast milk contains 
about 20-70 IU/L of vitamin D. An infant consumes 0.78kg (750 mL) of breastmilk in a day53.  
Table 2.1. Food sources of vitamin D  
Food IU per 100g IU per serving 
Cod liver oil ( 1 tsp) 10000 450 
Swordfish, raw (1 Oz) 558 158 
Salmon, sockeye, raw (1 Oz) 563 160 
Tuna fish canned in water ( 1Oz) 80 23 
Beef liver, raw ( Oz) 49 14 
Egg whole raw (1 large) 82 41 
Mushrooms, shiitake, dried ( 100 g) 154 154 
Mushroom, white, exposed to ultraviolet light, raw (100g) 1046 1046 
Whole milk vitamin D fortified ( 1 cup) 51 124 
Holic 2003 54 
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Metabolism of Vitamin D   
Role of Sunlight in Endogenous Vitamin D Synthesis 
 
UVB, a component of ultraviolet light with a wavelength range of 280-315 nanomole 
(nm), initiates the synthesis of vitamin D in the skin21. The ozone layer and atmospheric gasses 
(oxygen, Carbon dioxide) absorb most UVB light released from the sun before it reaches the 
earth’s surface. The amount of UVB light that reaches the ground surface of the earth varies by 
latitude, time of day and season. The angle of the sun is directly overhead near the equator and at 
noon. Hence, ambient UVB is more abundant near the equator, during summer and is at peak 
intensity closer to mid-day55. Other environmental factors that influence UVB availability include 
could cover, aerosols such as dust, smoke and air pollutant, altitude and ground surface 
reflectivity. Aerosols absorb UVB light. More UVB is available at higher elevations since it 
travels a shorter distance before reaching the ground, and chemicals in the atmosphere do not 
absorb it. Personal factors such as skin pigmentation, dress style, and sun-seeking behavior 
determine how much UVB reaches the skin; consequently leading to variable individual UVB 
exposure56.   
Cutaneous Production of Vitamin D  
Endogenous vitamin D (D3) synthesis takes place in the skin through the conversion of 7-
dehydrocholestrol, found in the dermis and epidermis of the skin, to pervitamin D3 by the action 
of UVB light (wavelength 390-450 nm) from the sun1,2,57. Per-vitamin D3 is formed when carbon 
bonds in 7-dehydrocholestrol are broken by UVB light resulting in a change in structure and 
chemical property (Figure 1) 2. Pre-vitamin D3 then undergoes thermal isomerization to form 
vitamin D3 (Cholecalciferol), which is further metabolized to produce active forms of vitamin 
D1,2,57. Excess vitamin D3 produced due to prolonged sun exposure is photo-isomerized to the 
non-vitamin D substances lumisterol and tachysterol which are biologically inactive 58. 
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Consequently, excessive exposure to sunlight does not cause vitamin D intoxication1. 
Furthermore, lumisterol and tachysterol can be converted back to pre-vitamin D3. Vitamin D3 
synthesis in the skin is affected by factors that reduce sun exposure such as pigmentation, 
latitude, and dress habits 1.  
 
Figure 1 Cutaneous synthesis of vitamin D. Source 2  
 
Response to Serum 25(OH)D to UVB exposure  
Ambient UVB is commonly expressed as the minimum erythemal dose (MED) and 
standard erythemal dose (SED). MED refers to dose required to produce a barely perceptible 
erythema in people with skin type 1 (white) (200 J/m2 of biologically effective UV radiation)59. 
MED is subjective since the determination of reddening of the skin might differ from person to 
person. Furthermore, it depends on individual sensitivity to UV radiation, site of radiation and 
skin pigmentation. Hence, values have to be defined for different skin types59. Holick showed that 
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full body exposure with 1MED could produce 10,000 -15, 000 IU vitamin in individuals with 
type 1 skin. However, those with skin type V will require more exposure to produce the same 
results55. One standard erythema dose (SED) is equivalent to an erythemal effective radiant 
exposure of 100 J/m2 (1 SED = 10 mJ/cm2). It is independent of skin color. Exposure dose in SED 
may cause erythema in fair skin but none in darker skin. 
Armas et.al.60 used participants with various skin tones to develop a formula below to 
predict change in serum 25(OH)D in response to a UVB dose and depending on skin lightness 
(L*).  
Z = b *X*Y, Where  
Z is Change in serum 25(OH)D in response to a UVB dose; 
X is UB dose in MJ/cm2 ans  
Y is skin lightness measures as L* 
Using this formula to attain a 30 nmol/L increase in serum 25(OH)D, a northern 
European person with an L* value of 70 would need 39 mJ/cm2 UV radiation. An African 
American with and L* score of 50 would require 55( mJ/cm2 )60. 
  
Absorption and Transport  
Endogenous vitamin D is transported in the blood stream bound to vitamin D binding 
protein (DBP) 61. Dietary vitamin D is absorbed in the same manner as dietary fats. It is 
emulsified in bile acids and is transported to the enterocyte as part of micelles. Vitamin D is then 
packaged as part of chylomicrons and enters systemic circulation through the lymphatic system 2. 
Once vitamin D reaches the blood stream, it is transported to the liver and other tissue bound to 
vitamin D binding protein (DBP)2,61.  
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Hydroxylation of Vitamin D  
Hydroxylation of vitamin D, first in the liver and then in the kidney, converts the 
biologically inactive vitamin to its active metabolite 1,25-dihydroxyvitamin D (1,25,(OH)2D), 
which is also referred to as Calcitriol2. Once vitamin D is transported into the liver by DBP, the 
25th carbon molecule is hydroxylated by hepatic 25-hydroxylase 2,57. Microsomal and 
mitochondrial forms this enzyme have been characterized 57. The product of the hydroxylation 
reaction is 25(OH)D (calcidiol). 25(OH)D is the major circulating form of vitamin D in the body. 
It is bound to the DBP in the blood stream and is transported to the kidney for the second 
hydroxylation step2,57. In the kidney, 25(OH)D is converted to 1,25,(OH)2D by the action of the 
enzyme 1α-hydroxylase 57.  
1, 25(OH)2D enters the circulation from the kidney and acts on peripheral target tissue. It 
acts as a ligand for the Vitamin D receptor (VDR) and regulates target cell genomic and rapid 
response generated through the activation of signal transduction pathways2. Another hydroxylase 
enzyme, 24-hydroxylase (CYP24), adds an hydroxyl group at carbon number 24 of both 
25(OH)D and 1,25,(OH)2D 57. This reaction converts the metabolites to less active, 24-
hydroxylated, products which are then excreted with bile through feces 57. Unlike that of 25-
hydroxylase, the activity of the enzyme 1α-hydroxylase is tightly regulated2,57. This tight control 
allows the body to regulate the production of 1,25,(OH)2D based on needs. The activity of 1α-
hydroxylase is elevated during vitamin D deficiency 2. Furthermore, when blood calcium levels 
are low Parathyroid hormone (PTH) increases the activity of 1α-hydroxylase2,57. The product of 
the enzymatic action of 1α-hydroxylase, 1, 25(OH)2D, negatively regulates the activity of PTH 
and the production of 1α-hydroxylase. Moreover, 1, 25(OH)2D increases activation of 24-
hydroxylase their by facilitating degradation of excess 25(OH)D and 1,25,(OH)2D 2,57. Fibroblast 
growth factor 23 (FGF23), which regulates phosphate metabolism and, is secreted when serum 
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phosphate levels are high and suppresses 1 1α-hydroxylase activity in the kidney 2. 1, 25(OH)2D 
exerts its function  
Physiological Functions of Vitamin D  
Skeletal Functions  
Vitamin D is important for the absorption of calcium and phosphorus. The action of 
1,25(OH)2D increases the efficiency of calcium absorption by up to 40% and that of phosphorous 
absorption by 80% 57. Two mechanisms have been proposed for regulation of calcium 
homeostasis by 1,25(OH)2D. By acting on the nuclear VDR 1,25(OH),2D up-regulates the 
expression of the calcium channel (TRPV6) and calcium binding protein (calbindin). Another 
mechanism is that 1,25(OH)2D promotes intestinal absorption of calcium by acting on a plasma 
membrane VDR which triggers a cascade of signal events that produces a second messenger that 
facilitates absorption1,57. Vitamin D also stimulates the Ca2+-Mg2+ ATPase pump though which 
calcium is released form the enterocyte to the extracellular fluid 62.  
Furthermore, 1,25(OH)2D stimulates the production of fibroblast growth factor 23 (FGF 
23) which intern increases phosphate excretion by decreasing the expression of phosphate 
transporters in the kidneys. When blood calcium concentrations are low 1,25(OH)2D acts on the 
nuclear VDR receptor found in osteoblasts (bone forming cells) and increases expression of 
RANKL ( receptor activator of nuclear factor-κB ligand). RANKL binds to the RANK receptor 
located on preosteoclasts and promotes maturation to osteoclasts (bone resorption cells). 
Osteoclasts then release calcium and phosphorus from the bone to the blood maintaining serum 
concentrations1,57. Figure 1 presents a pictorial representation of skeletal functions of vitamin D. 
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Figure 2: Skeletal functions of vitamin D. Adapted from 1 
 
Non-skeletal Functions  
The active metabolite 1,25(OH)2D is involved in many processes that extend beyond 
bone health. Most cells in the body have VDR and can perform the second hydroxylation step in 
vitamin D metabolism and convert 25(OH)D to 1,25(OH)D1. This discovery provides a 
mechanism for proposed non-skeletal functions of vitamin D such as reduction of risk of cancer, 
cardiovascular diseases, autoimmune diseases and infectious diseases1.  
Calcitriol is proposed to suppress proliferation and differentiation of cancer cells1,9. In 
vitro studies have shown that cancer cells have the VDR receptor and hydroxylase activity and 
can produce both 1,25,(OH)2D and calcitriolic acid. By acting on VDR 1,25,(OH)2D is proposed 
to inhibit angiogenesis and induce apoptosis in cancer cells1. Vitamin D also plays a role in the 
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innate immune system through enhancing of chemotaxis and the phagocytic capabilities of 
macrophages. It also promotes the production of antibacterial peptides cathelicidins which act 
destroy microbial agents such as Mycobacterium tuberculosis 1. Moreover, vitamin D decreases 
the Th1 and Th17 cell response and causes an increase in T regulatory cells. Thus it regulates 
cytokine and immunoglobulin synthesis. VDR is present in both the nucleus and plasma 
membrane of mammalian skeletal muscle cells and is proposed to play a role in muscle 
function1,9.  
Dietary Reference Intakes (DRI)  
The fact that vitamin D can be produced in the body aside from being obtained in the diet 
makes the establishment of DRI for the nutrient challenging 1. In 2011 the US Institute of 
Medicine’s (IOM) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium-
set Estimates Average Requirements (EAR), Recommended Dietary Intake (RDA), Adequate 
Intake (AI) and Tolerable Upper Intake (UI) recommendations for the US and Canada. The RDA 
for vitamin D was set at 600 IU (15µg). However, due to increased need, the RDA for older 
adults was set at 800 IU (20 µg). The EAR is 400 IU (10 µg) for all age groups. The AI for 
infants is 400 IU, and an RDA has not been set for this age group 11. The UI for vitamin D is 
4000IU/day.  
The 2004 World Health Organization (WHO) report on Vitamin and Mineral 
Requirements for Human Nutrition recommended a daily intake of 200IU as adequate to meet the 
needs of 98% of the general population. The report identified limited accuracy in estimating 
dietary intake and skin synthesis as major challenges for setting requirements for the general 
population 63. The WHO vitamin and mineral recommended dietary intake recommendations 
have not been updated since 2004.  
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Vitamin D Deficiency  
Estimation of global prevalence of vitamin D deficiency is difficult, since different 
investigators use different 25(OH) D concentration cutoffs to define deficiency. However, if 
25(OH)D concentration below 75nmol/L is used as indicative of deficiency (insufficiency), one 
billion people globally can be considered as vitamin D deficient or insufficient 1 .  
Calcium and vitamin D deficiency during pregnancy reduces fetal skeletal mineralization 
57. Prolonged vitamin D deficiency can cause growth retardation and skeletal deformities in the 
fetus and rickets during childhood 12. Among adults, deficiency can result in muscle weakness 
and osteomalacia. Furthermore, it can increase the risk of osteoporosis and fractures 1. Pregnant 
and lactating women and infants are considered to be at risk of vitamin D deficiency due to a 
number of reasons. Skeletal effects of vitamin D deficiency seen during pregnancy (after birth) 
persist in to early childhood (45). Non-supplemented infants are highly dependent on prenatal and 
postnatal maternal vitamin D status to meet their needs 12. Infants born to vitamin D-deficient 
mothers have lower levels of 25(OH)D at birth and are likely to be vitamin D deficient 64. Risk of 
deficiency in heightened in infants that are exclusively breastfed and do not receive vitamin D 
supplementation or sufficient sun exposure 19.  
Wagner et al. described three stages of vitamin D deficiency. In the first stage serum 
concentrations of 25(OH)D decrease, hypocalcemia and euphosphatemia are observed. However, 
1,25(OH) 2D might be increased or remain unchanged. In the second stage serum concentrations 
of 25(OH)D continue to decrease. PTH acts to maintain calcium through demineralization of 
bone. Alkaline Phosphatase (AP) increases slightly, and eucalcemia and hypophosphatemia are 
observed. In the last stage of deficiency serum concentrations of 25(OH)D are very low, and there 
is a marked increase in AP. Overt signs of bone demineralization, such as rickets, are observed. 
And finally, both hypocalcemia and hypophosphatemia are observed 13. Clinical signs of vitamin 
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D deficiency include; decrease in gut calcium absorption, low concentrations of serum 25(OH)D, 
increase in PTH, reduction in bone mass, increased risk of fracture, rickets, osteomalacia and 
osteopenia 1,13,15 
  Rickets was first described by Daniel Whistler in 1645 and Francis Glisson in 1650 14. 
Rickets is a preventable condition and is caused by inadequate intake of vitamin D and limited 
exposure to sunlight 13. Enlargement of the skull, enlargement of joints of long bones, curvature 
of spine and femur, and muscle weakness are classic signs of rickets 13,14. Rickets is a 
manifestation of extreme vitamin D deficiency. Thus deficiency exists before clinical signs of 
rickets are observed 13. The clinical symptoms of nutritional rickets are commonly seen between 6 
to 29 months. However symptomatic rickets is observed early in infancy. Before the development 
of overt clinical signs of rickets, hypocalcaemia and bone demineralization are observed in 
infants. Vitamin D deficiency presents as hypocalcemic seizures in infants younger infants13. 
Rickets is usually observed in two forms. In the first form, symptomatic hypocalcemia, seizures 
during rapid periods of growth, and increased vitamin D need are present. However no physical 
or radiological signs deficiency are observed. The second form of rickets is more chronic and is 
accompanied by decreased bone mineralization 13, 14.  
Vitamin D Toxicity  
Vitamin D toxicity usually occurs from excessive intake of supplements. Toxicity results 
in hypercalcemia and hypercalciuria which is associated with renal and kidney stones. Symptoms 
include anorexia, nausea, vomiting, thirst, polyuria, muscular weakness, joint pains, and general 
disorientation2,65. Studies have supplemented with 10, 000 IU/day for up to 5 months with no 
serious adverse reactions 66-68.  
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Factors That Affect Vitamin D Status  
Skin pigmentation, latitude, dress habits, time of day, season, urbanization, air pollution, 
lack of vitamin D fortified foods, and prenatal and postnatal maternal vitamin D deficiency are 
some of the factors that have been documented to affect vitamin D status 18. 
Skin Pigmentation  
A higher prevalence of vitamin D deficiency has consistently been reported for 
individuals that have darker skin pigmentation69. Individuals with a higher skin pigmentation 
have a higher melanin content in the skin which absorbs photons of light which are otherwise 
absorbed by 7-dehydrocholesterol to produce Vitamin D370. 
Hall et al. assessed the effect of skin pigmentation, UVB exposure, vitamin D intake, and 
other factors on serum 25(OH)D concentrations of young adults in the US, and reported need for 
a higher vitamin D intake for the maintenance of sufficient serum 25(OH)D concentrations in 
those with darker skin pigmentation 42. Furthermore, a high prevalence of vitamin D deficiency 
has been reported in dark skinned individuals that have migrated to areas with limited sun 
availability compared to those with lighter skin pigmentation 71. However, the extent of reduction 
in 25(OH)D concentrations due to skin pigmentation in areas with abundant sun exposure has not 
been widely explored.  
  Latitude and Season  
It has been proposed that amount of UVB light available for the endogenous production 
of vitamin D is limited in latitudes below 37O N, in the early morning and late evening and in 
winter 21. However, hypovitaminosis D has been reported in countries that are located well below 
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37O N and have abundant sunshine throughout the year 18-25. Binkley et al.47 assessed changes in 
serum 25(OH)D concentrations among 93 adults in Honolulu, Hawaii (latitude 21°). The study 
participants similar sun exposure but variable serum 25(OH)D concentration values. The authors 
noted variable responsiveness to UVB radiation despite abundant sun exposure stressing the need 
for consideration of other factors such as skin pigmentation together with sun exposure.  
Sun-Seeking Behavior  
Social, cultural and religious practices that affect dress habits limit sun exposure and can 
affect 25(OH)D concentrations43. Andiran et al., assessed vitamin D status of newborns (n=54) 
and mothers in Turkey, and found that 46% of mothers and 80% of newborns had 25(OH)D 
levels < 25 nmol/L. Maternal dress habit ( covering hair all the time and face sometimes) was 
found to be a major predictor of both maternal and infant vitamin D status. These effects were 
seen despite the availability of abundant sunlight (20). A high prevalence of vitamin D deficiency 
was also reported for veiled immigrant women 72. 
Markers of Vitamin D Status 
  25-Hydroxyvitamin D ( 25(OH)D) 
 Although 1,25-OH2-D is the metabolically active form of the vitamin, 25-
hydroxyvitamin D (25(OH)D) is the currently accepted marker of vitamin D status 73. This is so 
because 1,25-OH2-D levels can be elevated despite vitamin D deficiency because of secondary 
hyperparathyroidism. Serum concentration of 25(OH)D reflects dietary and cutaneous vitamin D 
and body stores. Thus total circulating 25(OH)D is composed of 25(OH)D2 and 25(OH)D3 , has a 
half-life of about 3 weeks and is the best reflection of vitamin D concentrations in the body 10. 
Furthermore, serum 25(OH)D has been shown to be very stable and unaffected by repeated 
freeze-thaw cycles 74. The reference categories (cutoffs ) used for the interpretation optimal 
concentrations of 25(OH)D vary widely in the literature 75. Most researchers have used 
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concentrations below 50 nmol/L as indicative of vitamin D deficiency 75. In 2011 the US Institute 
of Medicine’s (IOM) Committee to Review Dietary Reference Intakes for Vitamin D and 
Calcium concluded that the scientific evidence that supports the use of this cutoff was not 
adequate 11. The committee recommends the use of < 30 nmol/L as indicative of risk of 
deficiency-related to bone health. Intakes above 50 nmol/L are indicative of vitamin D 
sufficiency (Table 1) 11 .  
Serum concentrations of 25(OH)D are affected by sun exposure, skin pigmentation, 
season, latitude, dietary intake and other factors such us adiposity 17,76 . Different types of assays 
are used to assess serum 25(OH)D. Radioimmunoassay (RIA), high-performance liquid 
chromatography (HPLC) and liquid chromatography coupled with mass spectrometry (LC/MS) 
are some of the widely used techniques for the quantification of serum 25(OH)D 77. The 
radioimmunoassay method uses a synthetic antigen that generates an antibody specific for 
25(OH)D2 and 25(OH)D3 77. HPLC and LC/MS are direct detection methods for the 
quantification of 25(OH)D2 and 25(OH)D D3 77.  
 
Table 2.2. Classification of 25(OH)D concentrations  
Concentration Health status  
<30 nmol/L Vitamin D deficiency leading to rickets and osteomalacia 
30–50 nmol/L 
 
Inadequate for bone and overall health in healthy individuals 
≥50 nmol/L 
 
Considered adequate for bone and overall health in healthy 
individuals 
Source 11 
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Calcium (Ca) 
The duodenum and jejunum (proxaima1) are primary sites of calcium absorption. 
Calcium absorption is regulated by the action of calcitriol and PTH. During lactation calcium 
requirements are high and absorption is increased to meet these requirements. When dietary 
calcium intakes are low (< 400 mg/day) intestinal calcium absorption is stimulated through the 
action of PTH. Hence PTH levels will be elevated2. Dietary calcium bound to fiber, phytate, 
oxalate and fatty acids is excreted in feces. Hence these substances inhibit calcium absorption 
(although some of the Ca bound to fiber can be hydrolyzed and absorbed) 62 . Some of the Ca 
bound to insoluble fiber is absorbed in the colon (4-10%) when its liberated when colonic 
microorganisms ferment fiber2,78. Overall 30% of calcium from the diet is absorbed. Blood 
ionized calcium concentration is tightly maintained between 1.1-1.3mM for physiological process 
that depend on calcium, including muscular function and bone mineralization to be performed 79 .  
Phytate (Phytic acid) which is the storage form of phosphorus, chelates Ca and inhibits its 
absorption2. Plant-based diets are usually high in phytate. A Dietary Phytate: Ca ratio greater than 
0.2 is indicative of reduced ca bio-availability in the diet (critical value)80,81. Phytic acid (IP6) is 
hydrolyzed to produce degradation products IP5 to IP1 during digestion. These degradation 
products are formed when phosphate groups are removed from phytic acid (IP6). With the 
removal of phosphate groups, chelation potential is reduced (IP6 a more potent chelateor than 
IP5)80.  
Parathyroid Hormone (PTH) 
Blood calcium concentration is tightly controlled through the action of PTH, calcitriol, 
and calcitonin. A decrease in blood ionized calcium and an increase in phosphate triggers release 
of PTH by chief cells of the Parathyroid gland 11,79. PTH directly increases blood calcium 
concentration by promoting calcium breakdown in the bone and subsequent release to the blood 
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and by reducing urinary calcium loss. PTH exerts an indirect influence by stimulating the 
production of calcitriol in the kidneys11. Calcitriol increases calcium absorption in the enterocyte 
and together with PTH acts on the bone and kidney to increase the release of calcium to the 
extracellular fluid 11,79. When blood calcium levels are elevated free calcium binds to Ca-sensing 
receptors (CaSR) on the parathyroid cells and triggers cellular changes that increase intracellular 
calcium and suppress secretion of PTH. Elevation of intracellular calcium levels intern activates 
calcium sensitive proteases which degrade PTH in the secretary vesicles of chief cells 82.  
       PTH stimulates the production of 1,25(OH)D in the kidneys and bone calcium reabsorption 57 
through the activation of osteoblasts which in turn stimulate the maturation of osteoclasts. PTH 
activated mature osteoclasts stimulate the production of 1,25(OH)2D in the kidneys 57. As it is 
with calcium, elevated levels of calcitriol suppress PTH secretion. Both calcium and calcitriol 
inhibit the transcription of PTH gene and reduce levels of PTH in circulation. When vitamin D 
deficiency is present, calcium absorption is reduced and PTH is elevated to maintain blood 
calcium concentrations. Fibroblast growth factor 23(FGF 23) increases excretion of phosphate in 
the kidneys and consequently inhibits PTH secretion11. The action of PTH in target cells ( Bone, 
Kidney) works thorough activation of a signaling pathway in the cells. PTH attaches to the 
PTH/PTHrP receptor located in the cells. Through conformational changes in the G protein-
coupled receptor and subsequent production of the second messenger cAMP, protein kinases that 
can activate or deactivate enzyme11. PTH promotes phosphate excretion in the kidneys and 
reduces excretion of calcium by increasing reabsorption2,11 Plasma 25(OH)D concentrations are 
inversely associated with PTH concentrations until 25(OHOD concentrations are around 75-100 
nmol/L. After these concentrations PTH concentrations remain constants and do not decrease 
with increasing 25(OH)D concentrations 1. 
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Vitamin D and calcium requirements during Lactation  
         Calcium needs are high during lactation since a lactating woman needs to meet the calcium 
need of the growing infant as well as her own. Up to 200-300 mg of calcium in a day is 
transferred into breastmilk, most of it from maternal bone83,84. Lactating women lose up to 10% 
of their bone mineral density to provide sufficient calcium in breast milk for the rapidly growing 
infant83,85. However due to physiological adaptations that take place in the body to meet this high 
demand calcium and vitamin D requirements are not higher. Bone loss during lactation is restored 
to pre-pregnancy and lactation states, and no residual effects on bone health are seen83,84.  
        Bone resorption during lactation is mainly directed by increased secretion of parathyroid 
hormone-related protein (PTHrp) during nursing and reduced estradiol secretion. Elevated PTHrp 
and low estradiol stimulate bone resorption83,85. Intestinal calcium absorption is lower than 
pregnancy but still higher than non-pregnant women, and renal absorption is elevated. For 
western European women PTH concentrations are typically low and increase during lactation85. 
Levels are elevated in women with very low calcium or high phytate intake86. Calcitriol levels are 
elevated during pregnancy but return to normal during lactation. 25(OH)D concentrations are 
stable. Calcitriol does not pass into breastmilk. Vitamin D can penetrate breastmilk relatively 
easily compared to 25(OH)D85. 
Bone and bone turnover markers  
Bone tissue has two components. The organic component contains bone cells, proteoglycans 
and collagen87,88. It is repos bile for flexibility of bone and contributes to a third of dry weight of 
bone. The inorganic component of bone contains hydroxyapatite (mineral component) and is 
important for weight bearing. It is the source of calcium (99%) and phosphorus (85-95%) for 
extracellular fluids89 Bone is comprised of cortical and trabecular bone. Cortical bone is the outer 
layer, which is a thick, dense, highly calcified matrix. Cortical bone accounts for 75% of skeletal 
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weight. Trabecular bone, found in the interior of bone, has a structure resembling sponge. 
Cortical bone serves as mineral reservoir while trabecular bone is metabolic active88.  
Bones in a continual state of change modeling and remodeling. Bone modeling results in 
linear and circumferential growth during childhood and adolescence. Bone remodeling takes 
place in response to changes in forces (strains, maintain Ca concentration) applied to bones. In 
order to maintain stability and integrity of bone, it is constantly undergoing remodeling. About 
10% of bone material is renewed each year. During bone, remodeling Osteoblasts lay down new 
bone and osteoclasts remove old bone. Bone formation and bone resorption typically occur 
simultaneously. Bone remodeling is uncoupled in diseases such as osteoporosis and also during 
lactation89.  
 
Markers of bone turnover 
Bone turnover markers are biochemical products that reflect the metabolic activity of 
bone. They can be measured in blood or urine. Bone turnover markers are categorized in two; 
markers of bone formation or markers bone resorption90. Markers of bone formation are direct or 
indirect products of active osteoblasts and reflect different aspects of osteoblast function. Bone-
specific alkaline phosphatase (BAP) and osteocalcin (OC) are two of the most widely used bone 
formation markers. OC is a non-collagenous protein in bone matrix and is produced by 
osteoblasts during bone formation. Some portion of OC leaks into the extracellular compartment, 
where it can be measured. BAP is released when newly formed osteoid undergoes maturation 
followed by mineralization90. It is secreted by secreted by osteoblasts into the extracellular fluid 
and can be measured in serum. Alkaline phosphatase has hepatic and bone isoforms. The bone 
isoform is an indicator of bone formation. C-terminal and N-terminal cross-linking telopeptides 
(CTX, NTX) of the type I collagen molecule is a commonly used bone resorption markers. It is a 
degradation product of type I collagen.  
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Maternal Vitamin D Supplementation during Lactation  
Increased vitamin D needs during infancy and the effect of maternal vitamin D status on 
breastmilk vitamin D makes lactation a critical period for vitamin D deficiency. Studies that 
analyzed breastmilk vitamin D have mostly been carried out in countries with a temperate climate 
where season significantly influences vitamin D status. These studies have reported that 
breastmilk vitamin D content ranges from 5- 80 IU/L and have shown that breastmilk vitamin D 
is low in mothers that themselves are vitamin D sufficient91,92. Maternal vitamin D 
supplementation during lactation can be a feasible intervention to reduce vitamin D deficiency; 
especially in counties where foods are not fortified with vitamin D93. 
Several randomized controlled trials have been conducted where lactating mothers with 
limited sun exposure were supplemented with vitamin D (Table 2.5 ). These studies showed 
improvements in maternal and infant 25(OH)D through maternal supplementation. Hollis & 
Wagner 91 supplemented lactating mothers (n=18) with either 1600 IU D2 & 400 IU D3 (G1) or 
3600 IU D2 & 400 IU D3 (G2) for 3 months. Supplementation increased circulating 25(OH)D 
concentrations for both mothers and infants. The antirachitic activity of milk from mothers 
receiving 2000 IU/d vitamin D increased by 34.2 IU/L and by 94.2 IU/L for those in group 2. 
Infant circulating 25(OH)D2 concentrations reflected maternal intake and the amount contained 
in the milk.  
In another 6 months supplementation study, lactating mothers (n=19) were supplemented 
with 400 IU vitD3/day (control) or 6000 IU vitD3 + 400 IU vitD3/day (part of a prenatal 
vitamin). Infants of mothers in the control group were supplemented with 300 IU vitD3/day 92. 
25(OH)D was measured at 7 time points every month after enrollment. In the control group 
maternal 25(OH)D reduced over visits before increasing (lowest 25.9 ng/ml + 9.1). Change in 
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25(OH)D from baseline to visit 7 was: 32.2 ng/ml to 38.4ng/ml. Infants supplemented with 
vitamin D, and infants whose mothers were in the high dose group had a similar increase in 
25(OH)D. Milk antirachitic activity (IU/L) increased significantly in the high-dose group (82.4 
IU/L to 873.5 IU/L) compared to control group (59.6 IU/L to 76.3 IU/L). In a follow-up study 
they showed that when mothers were supplemented with 6400 IU VitD3/Day for 6 months 
improvements seen in their infants were similar to infants that received 400IU VitD /day94. 
 Saadi et al.28 conducted a combined maternal and infant supplementation study in Unite 
Arab Emirates (UAE). In the study lactating women (n = 90) were supplemented with 2000 
IU/daily or 60 000 IU/monthly. All infants received 400 IU/ daily for the duration of the study 
period (3 months). Both daily and monthly maternal supplementation significantly increased 
25(OH)D concentrations. Supplementation at this dose also reduced infant vitamin D deficiency 
and did not result in hypervitaminosis D. 
Vitamin D Status Assessment in Ethiopia  
  Only a limited number of studies have assessed markers of vitamin D status in Ethiopia 
probably because sunshine is abundant in Ethiopia and vitamin D deficiency is thought to be 
unlikely to occur. Muhe et al.35 assessed the prevalence of rickets in children with pneumonia and 
compared children which did not have pneumonia in a case-control study and reported that the 
prevalence of rickets was significantly higher in children with pneumonia. Furthermore, duration 
of exclusive breast feeding and crowding were significantly different between groups (Table 2.6).
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Table 2.3 Effects of vitamin D supplementation of lactating women on vitamin D markers  
 
Authors County Intervention Timing Effect on maternal Effect on Infant Effect on milk 
     25(OH)D 25(OH)D activity 
        
  Mothers Infants     
        
Hollis US G1: 2000IU/day  1 month G1: 69 to 90 nmol/L G1: 32 to 70 G1: 36 to 70 
(2004) 92 
 
(1600 IU VitD2 & 
 postpartum  nmol/L IU/L 
  to 3 months    
n =18 
 400 IU VitD3)   
G2: 82 to 111 nmol/L 
  
 
Vs. 
  
G2: 33 to 77 G2: 40 to 135   
__ 
  
  
G2: 4000 IU/day 
  nmol/L IU/L 
       
  (3600 IU VitD2 &      
  400 IU VitD3)      
        
Wagner US G1: 400 IU  1 months G1: 80 to 96 nmol/L G1: 33 to 108 G1: 59.6 to 76.3 
(2006)93  vitD3/day G1: 300 postpartum G 2: 85 to 147 nmol/L nmol/L IU/L 
  Vs. IU to 6 months  G2: 35 to 115 G2: 82.4 to 
n =19  G2: 6400 IU vitD3/day   nmol/L 873.5 IU/L 
  vitD3/day      
        
Basile US G1: 2000 IU  1 month G1: 56 to 100 nmol/L   
(2006)96  VitD3/ day  postpartum    
  
Vs. 
 to 3 months    
    
G 2: 71 to 108 nmol/L __ __ 
n =25 
 
G2: 4000 IU 
  
 
__ 
    
  VitD3/day     
        
Saadi UAE G1: 2000 IU  1 month G1: 27 to 42 nmol/L G1: 14 to 50  
(2007)28,97 
 VitD2/day 
G1 and 
postpartum  nmol/L  
 
Vs. 
to 3 months    
n =90 
 G2: 400  
G 2: 23 to 38 nmol/L 
 
___  
G2: 60 000 IU 
IU  
G 2: 14 to 45   vitD3/day    
  VitD2/ Month    nmol/L   
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Authors County Intervention Timing Effect on maternal Effect on Infant Effect on milk 
     25(OH)D 25(OH)D activity 
             
  Mothers Infants          
            
Oberhelman US G1: 5000 IU  28 days G1: 73 to 125 nmol/L G1: 43 to 100 Vitamin D3 
  
VitD2/day 
      
nmol/L 
  
(2013)98 
       
G1: 18 to 20  
Vs. 
        
n =40 
 
___ 
 
G 2: 73 to 103 nmol/L 
  nmol/L 
 
G2: 150, 000 IU 
 
G 2: 40 to 100 G2: 18 nmol/L         
         nmol/L (no change at 
           28 days) 
           
Czech- Poland G1: 400 IU G1 and 6 months Mean change     
Kowalska  VitD2/day G2: 400  
G1: 14 + 21 nmol/L 
  
___ 
 
(2014)99 
 
Vs. 
IU     
 
vitD3/day 
         
  G 2: 27 + 24 nmol/L     
n =174 
 
G2: 1200 IU 
      
           
         
Hollis US G1: 400 IU G1: 400 4 to 6 weeks At visit 4 At visit 4   
(2015)95 
 VitD3/day IU postpartum G1: 87 to 80 nmol/L G1: 34 to 109   
 
G3: 6400 IU 
VitD3/day to 6 months 
G 2: 99 to 149 nmol/L 
nmol/L   
n =334 
   G 2: 40 to 109   
 VitD3/day   
At visit 7 
  nmol/L   
      At visit 7 
___ 
 
       
            
         G1: 36 to 109  
G1: 89 to 79 nmol/L nmol/L 
 
G 2: 99 to 151 nmol/L G 2: 41 to 109 
 
 nmol/L 
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In a follow-up study conducted in the same facility, Lulseged & Fitwi 34 identified 
underweight[OR = 12.7 (95% CI 4.47-11.08)], and lack of exposure to the sunshine [OR = 3.5 
(95% CI 1.33-5.84)] as major predictors of rickets. Low calcium intake in children with and 
without rickets has also been reported 95. In 1999 Feleke and colleagues36 compared serum 
25(OH)D concentrations of Ethiopian adults and pregnant women with their Norwegian 
counterparts. Mean 25(OH)D concentrations for Ethiopian participants was 23.5 nmol/L for 
adults (n=30) and 25 nmol/L for pregnant women (n=31) where as it was 81 nmol/L and 36 
nmol/L for Norwegian adults and pregnant women36.  In a recent assessment of vitamin D status 
of women of reproductive age, 15.8% had 25(OH)D levels below 30 nmol/L and 69.4% had 
levels between 30-50 nmol/L38. Table 2 presents a summary of studies.  
 
  
32 
 
Table 2.4 Vitamin D studies in Ethiopia 
Author  Target group  Major finding  
Muhe 
(1997)35  
Children with Pneumonia 
(cases) (n=521) 
Controls (n=500) 
Children with Pneumonia were 13.11 more 
likely to have rickets. 
Vitamin D might be a predisposing factor for 
Pneumonia  
Lulseged 
(1999)34  
Children with rickets (Cases) 
( n= 157)  
Lack of exposure to sunshine and protein 
energy malnutrition associated with rickets.  
Feleke 
(1999)36 
Adult men (n=30) & pregnant 
women (n=31) 
Adults : mean 25(OH)D 23.5 nmol/L 
Pregnant women : mean 25(OH)D 25 nmol/L 
Belachew ( 
2005)95  
Cases (n=30) Children with 
rickets 
Controls (n= 104)  
Low calcium intake in both cases and controls.  
Children with rickets had limited sun exposure  
Pruitt 
(2007)49 
Lactating women (n=108)  39% vitamin D insufficiency 
G.Egziabher 
(2013)38 
Reproductive age women 
(n=205) 
15.8% < 30 nmol/L  
69.4% < 30-50 nmol/L 
Wakayo 
(2013)37 
Children (aged 11-18) 
(n=174)  
  42% < 50 nmol/L 
61.8% < 50 nmol/L in urban 
 21.2% < 50nmol/L in rural  
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CHAPTER III 
 
 
MATERIALS AND METHODS  
 
Trial Design  
The study was a parallel group, double-blind, randomized, controlled trial conducted 
among Ethiopian lactating women (Trial registered at clinicaltrials.gov NCT02210884). 
Participants were randomized to one of the study groups and received 15,000 IU vitamin D3 or 
placebo capsules weekly. The study trial profile shows participant enrollment (Figure 3.1). 
Participants were enrolled in the trial within two weeks after delivery and were followed for 12 
months. 
Sample Size  
The endpoint of this study was to assess mean differences in 25(OH)D concentrations 
between the two study groups (placebo and treatment). Hence sample size was estimated for a 
repeated measure, between factors ANOVA test using the software G*Power version 3.0.10 
(Franz Faul, Kiel University, Kiel, Germany). A sample size of 108 was calculated to be adequate 
using a small effect size of 0.25, a 0.05 level of significance and 90% power. After a 15% 
adjustment for a possible loss to follow-up, the final sample size for the study was 126 (63 in 
each group).
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Study Setting  
The study was conducted in four rural communities located in Hawassa Zuria Woreda 
(Hawassa area district), Southern Ethiopia. Ethiopia has an estimated population of 
102,374,04496. Approximately 86% of the population reside in rural areas 39. Agriculture is the 
primary source of income for the country, and 39% of the population lives below the poverty line 
of $ l.25 per day 97. Health care providers widely promote exclusive breastfeeding for the first six 
months of life. According to the 2016 Ethiopian Demographic and Health Survey, 58% of all 
children under the age of 6 months are exclusively breastfed 98. Furthermore, 91% of children 
aged 12-17 months were currently breastfeeding 98. Foods are not fortified with vitamin D in 
Ethiopia. 
Ethiopia has two main seasons: dry and rainy. The small rainy season extends from 
February to May. June is usually dry and is a transition period between the small and main rainy 
seasons. Heavy rainfall and dense cloud cover characterize the main rainy season, which extends 
from July to October. The dry season begins in November and ends in January. The country has 
UV exposure adequate to produce sufficient vitamin D all year round .  
The study areas, Alamura, Finchawa, Chefe Koti Jebesa, and Tullo, are located near 
Hawassa town (7oN, 38oE), which is the capital of the Southern Region. Subsistence farming is 
the main source of income for the study population. Maize (Zea maysL.) and enset (Enset 
ventricosum) are the main staple foods 50. A cross-sectional analysis of vitamin D status of 
women in the study area reported that 84% of the participants had 25(OH)D concentrations below 
50 nmol/L 38.  
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Figure 3.1: Study trial profile   
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Study Participants  
Lactating women who delivered during the enrollment period and met inclusion criteria 
were recruited. Eligibility was determined using the inclusion and exclusion criteria listed below. 
 
Inclusion criteria:  
1) Currently breastfeeding and plan to breastfeed for 12 months.  
2) Available for enrollment within two weeks after delivery; 
 3) Intend to reside in the study area for the duration of the study; 
4) Apparently healthy.  
Exclusion criteria:  
1) Any self-reported chronic or acute disease condition such as liver and kidney disease, diabetes, 
tuberculosis, and HIV; 
2) Not planning to breastfeed; 
 3) Twin births.   
Recruitment, Randomization and Enrollment  
At the start of the study, Health Extension Workers (HEW) and Community Health 
Volunteers (CHV) conducted a mini-census to identify all pregnant women in the study areas 
expected to deliver within three months. Additionally, HEW and CHV compiled a weekly list of 
all women who delivered in the study area during the enrollment period. Screening and 
enrollment was carried out from October 4th, 2014 to January 17th, 2015. Enrollment extended 
over three and half months in order to meet the target sample size from the four study kebeles. 
The study team assessed eligibility using a screening questionnaire and provided all the 
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information (in the local language) eligible mothers needed to make an informed decision about 
participation in the study. Written consent was mandatory for participation.  
 A non-participating faculty member of the School of Nutrition, Food Science and 
Technology performed randomization for the study. The website Randomization.com 
(http://www.randomization.com/ ) 99 was used to generate a simple randomization allocation 
sequence, which consisted of a number (1 to 126) with a corresponding intervention code (AB or 
CD). To conceal the sequences before allocation, they were sealed in opaque envelopes that were 
numbered from 1 to 126 on the outside. When a mother met the screening criteria and gave 
informed consent, she was assigned an envelope that contained an allocation sequence. Envelopes 
were allocated to participants sequentially following the numbering on the outside of the 
envelopes. After an envelope was assigned to the mother, the principal investigator opened the 
sealed envelope and recorded the mother’s intervention code in a separate master sheet. The 
mother's name and other personal details were registered on a card and placed in an envelope. All 
envelopes were kept locked. Assignment to one of the intervention groups was considered as 
official enrollment in the study. 
Provision of Study Intervention  
After enrollment, lactating women in the treatment group were given 15,000 1U Vitamin 
D3 capsules weekly while those in the placebo group received capsules containing no vitamin D 
every week for 12 months. Pure Encapsulations (Pure Encapsulations Inc., Sudbury, MA, USA) 
formulated both the treatment and placebo capsules, which were identical in appearance. 
Community Research Workers (CRW) made weekly home visits and gave the intervention to the 
lactating women. To guarantee compliance, mothers took the capsules while the CRW watched. 
Potential reactions to the intervention were assessed during these weekly home visits.  
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Compliance and loss to follow-up  
Loss to follow-up was calculated by dividing the number of participants that were lost to 
follow-up by the number that received the intervention [70]. Total study loss to follow-up was 9 
%. Loss to follow-up was 8% in the Vitamin D group and 6% in the control group. Overall 
compliance (proportion of capsules consumed to distributed) was 99%. The vitamin D group had 
99.2% compliance, and the control group had 99 % compliance.  
Outcome assessment  
Data were collected from October 2014 to January 2016 (15 months). Outcome and 
explanatory variables were measured during four data collection time points: Baseline, three 
months, six months and end-line (12 months) (Table 3.1). 
Table 3.1 Outcome assessment time points  
 
 In addition to these measurements, infant morbidity and infant gross motor development 
were assessed during weekly home visits. Because participants were enrolled within two weeks of 
delivery baseline assessment was conducted in participant’s homes. All subsequent assessments 
were performed in the local central health post. Table 3.2 provides a summary of variables and 
assessment times.  
  
Assessment period Duration Season 
 
Baseline assessment 
 
October 8, 2014 – January 17, 2015 Long dry season (Bega) 
3 month January 16, 2015 -- April 22, 2015 Small rainy season (Belg) 
6 month April 23, 2015 – July 23, 2015 Main rainy season (Kiremt) 
12 month 
 
October 15, 2015-January 5, 2016 Long dry season (Bega) 
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Table 3.2. Outcome assessment timeline  
Maternal Study procedures Baseline 3 months 6 months  End-line 
Maternal blood √ √ √ √ 
Maternal Urine  - √ √ √ 
Breast milk  √ √ √ √ 
Maternal anthropometry √ √ √ √ 
Skin reflectance  √ √ √ √ 
Dietary assessment: Weighed food records  - √ - - 
Questionnaires - √ - - 
Questionnaires: Infant feeding practices - - √ √ 
Ultraviolet (UVB) exposure  - - - √ 
Infant Study procedures Baseline 3 months 6 months  End-line 
Infant blood - - - √ 
Infant skin reflectance  - - - √ 
Infant anthropometry √ √ √ √ 
Assessment for rickets  - - - √ 
Motor developmental milestones Weekly 
Infant morbidity  Weekly 
 
Biological sample collection, initial separation, and storage  
Maternal venous blood samples were collected at baseline, 3, 6 and 12 months using 
lithium heparin coated S-Monovette tubes (7.5 ml) (Sarstedt, Inc., Newton, NC.). Infant venous 
blood samples were collected at end-line using S-Monovette (4.5 ml) neutral tubes. Sterile 
butterfly needles (Sarstedt, Safety-Multifly, 21-23G) were used to draw blood. A topical numbing 
anesthetic cream (Lidocaine 2.5% and Prilocaine 2.5% (EMLA) cream) was also applied a few 
minutes before the draw to reduce discomfort. An experienced laboratory technician collected the 
blood samples. Samples were stored in a box with ice until initial separation. They were then 
centrifuged at 2000 x g for 10 minutes at room temperature to separate plasma or serum. Maternal 
spot urine samples were collected at 3, 6, and 12 months. Urine samples were provided by the 
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participants in disposable plastic cups and were then transferred by a research assistant into 
polyethylene vials. All samples were stored at -15 to -20 OC at Hawassa University before 
shipment in dry ice to Oklahoma State University for further analysis. 
 
Anthropometric measurements  
  Research assistants measured maternal height, weight, mid-upper arm circumference 
(MUAC), wrist circumference and elbow breadth at baseline, 3, 6 and 12 monhts. Infant weight 
and MUAC were also measured at these time points. Infant recumbent length was measured at 3, 
6 and 12 months. Measurements were taken using standardized techniques 100 and calibrated 
equipment. Height and length were measured to the nearest 0.1 cm using the Shorr measuring 
board (Shorr Productions, Olney, MD, USA). Weight was measured to the nearest 0.1kg using a 
digital scale (SECA Uniscale, UNICEF, Copenhagen). At baseline, infant weight was measured 
to the nearest 0.01kg using a portable baby scale (SECA354, UNICEF, Copenhagen). Subsequent 
measurements were taken on the 0.1 kg person scale. A non- stretchable Teflon measuring tape 
was used to measure MUAC and wrist circumference. Elbow breadth was measured using a 
skinfold caliper. Infant anthropometric indices of length-for-age, weight-for- age and BMI-for-
age were calculated from the measurements using the WHO Anthro software (Version 3.2.2.). 
Assessment of rickets  
At end-line, a pediatrician screened the infants for clinical signs of rickets. Signs that 
were examined were delayed fontanel closure, wrist widening, rachitic rosary, double malleoli, 
bow legs, ping-pong sensation on the skull (craniotabes), and delayed teeth eruption or dental 
abnormalities. The pediatrician made a clinical diagnosis based on the presence of a combination 
of two or more symptoms.  
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Infant morbidity  
Trained CRWs assessed the incidence of common childhood illnesses weekly during 
home visits. Illnesses were defined based on the WHO Integrated Management of Childhood 
Illness (IMNCI) guidelines101. CRWs asked the mother the number of times the infant had 
vomited, coughed, and had diarrhea in the past seven days. Vomiting was defined as the forceful 
evacuation of stomach contents. Reflux, which is common in breastfeeding infants was not 
counted as vomiting. Diarrhea was defined as three or more loose stools in a day. The CRWs also 
observed if the child had a runny nose at the time of the visit and measured temperature to check 
for fever. Temperature was measured using a non-contact forehead thermometer. A stopwatch 
with a countdown timer was used to record breathing rate (The number of breaths per minute) of 
infants. Sick children were referred to the local health post or hospital for treatment.    
Infant gross motor development  
Attainment of gross motor milestones by infants was assessed by CRWs weekly (See 
Appendix 2 for testing procedures and criteria). The first four milestones (Table 3.3) were taken 
from the Denver Developmental Scale screening test II 102 The remaining milestones were 
adopted from the World Health Organization (WHO) multicenter growth reference study 63.  
Table 3.3 Gross motor developmental milestones  
No. Motor milestone  No. Motor milestone  
1. Raising head when on front 5. Sitting without support 
2. Bearing weight on legs 6. Hands and knees crawling 
3. Sitting supported by arm 7. Standing with support 
4. Turning and rolling over 8. Standing unsupported 
  9. Walking supported 
  10. Walking unsupported 
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Determination of skin pigmentation  
Skin reflectance (pigmentation) was measured at three different locations (middle of the 
upper inner arm, lower outer hand, and in the middle of the forehead) using a portable ColorTec 
PCM+TM color meter (ColorTec Associates, Inc., Clinotn, NJ). The colorimeter quantifies skin 
pigmentation using the International Commission on Illumination (CIE) LAB color space. The 
LAB color space describes all perceivable colors in three dimensions (axes) L* (black to white), 
a* (red to green) and b* (yellow to blue). L* indicates skin lightness and values can range from 0 
to 100 with zero indicating perfect black and 100 indicating perfect white 103. A person with a 
lighter skin color will hence have a higher L* value compared to a person with a darker skin tone. 
L* values have been shown to be highly correlated with skin melanin content and has been used 
to relate skin pigmentation with 25(OH)D concentrations 42,60. L* values were used as an 
indicator of skin color in this study as well.  
 
Ultraviolet (UVB) exposure  
Maternal personal UVB exposure was measured using personal electronic dosimeters. 
The dosimeters measure erythemally-weighted UV irradiance at 8-second intervals. The 
electronic dosimeters were placed on each participant’s wrist (like a watch), and they were 
instructed not to take them off for five days. Clothing worn during this time was assessed using 
questionnaires on the fifth day to estimate the portion of body surface area exposed to UVB. The 
daily UVB exposure data recorded on the dosimeters was then converted into standard erythemal 
dose (SED). Average usual SED exposure was calculated as mean of the five daily values. One 
standard erythema dose (SED) is equivalent to an erythemal effective radiant exposure of 100 Jm2 
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Dietary intake assessment  
At 3 months follow up a one day weighed food record (WFR) was taken to assess dietary 
intake of all participants. A second nonconsecutive WFR was taken from 40 randomly selected 
participants to allow estimation of the prevalence of inadequate intake (population percentage at 
risk). Weekdays and weekends were represented in order to account for any day-of-the-week 
effects. A diet worker stayed in a participant’s home from 6 am to 7 pm and measured and 
recorded every food and beverage consumed during the day using a digital balance (Model CS 
2000, Ohaus Corporation, USA). The Ethiopian Food Composition Table Part III104 and Part 
IV105 were used to calculate nutrient intakes using Food processor (Version 8.1, ESHA Research 
Inc, Salem, OR).  
Questionnaires  
Trained research assistants administered questionnaires to mothers in the local language 
at 3, 6 and 12 months. The questionnaires were used to assess demographics, socioeconomic 
status, water and sanitation practices, infant and maternal sun exposure behavior, dress habits, 
breastfeeding practices, complementary feeding practices, diet diversity and household food 
security. Food security was assessed using the Household food insecurity access scale (HFIAS) 
106. Dietary Diversity was assessed using the FAO individual food security assessment tool 107. 
Percent Body Surface Area Exposed (BSAE) was calculated from clothing data collected using a 
modified version of the rule of nines used for burn assessment 108.   
Laboratory Analysis  
Maternal 25(OH)D concentrations were measured in samples obtained at baseline, 6 and 
12 months. Bone turnover markers were measured in baseline and end line samples. Urinary 
calcium, phosphorus, and creatinine values were measured in samples obtained at 3, 6 and 12 
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months. Plasma albumin concentration was determined for samples collected at all four data 
collection time points. Serum 25(OH)D, bone-specific alkaline phosphatase (BAP) were 
determined from end-line infant serum samples.  
 25-hydroxi vitamin D (25(OH)D) 
Total plasma 25(OH)D concentration were determined using new VDSP (Vitamin D 
Standardization Program) certified Immunodiagnostic Systems (IDS) 25-Hydroxy Vitamin DS 
ELISA Kits (Immunodiagnostic Systems (IDS) Inc. Gaithersburg, MD) . The method is an 
indirect detection method that uses a competitive ELISA technique. Samples, calibrators and 
quality controls (QC) were first diluted with a biotin labeled 25(OH)D. The diluted samples were 
then pipetted into a 96- well plate coated with a highly specific sheep 25(OH)D. The plate was 
then incubated and washed. Enzyme labeled avidin was added to selectively bind biotin. Color 
was developed by adding a chromogenic substrate (TMB). The reaction was stopped, and 
absorbance was read at 450 nm (reference 650 nm) using a plate reader (Synergy HT, BioTek 
Instruments Inc., Winooski, VT). Color intensity was inversely proportional to 25(OH)D 
concentrations. A 4 parametric logistic (4PL) curve was used to calculate results.  
To maintain maximum assay performance our lab participated in the Centers for Disease 
Control and Prevention (CDC) Vitamin D Standardization Certification Program (VDSP)109. As 
part of the standardization program, seven external quality control materials were included along 
with samples in each ELISA plate. Four of these control materials were obtained from the 
National Institute of Standards and Technology (NIST) standard reference material 972a, and 
three serum samples were provided by the VDSCP program. No significant bias (average 
deviation from a true value) was noted for the seven quality control samples across all plates. The 
individual sample bias ranged from -8.9% to 15.0%. The imprecision (CV) from the replicate 
measurements was within suggested criteria of <10% across all seven samples (range 2.4-7.7%). 
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Parathyroid hormone (PTH)  
Maternal parathyroid hormone (PTH) concentrations were measured in plasma using 
Immutopics ELISA kits (Immutopics Inc, San Clemente, CA). The kit measures activity of intact 
PTH (PTH 1-84). Standards, controls and samples were pipetted into Streptavidin coated 96 well 
plates. A PTH antibody solution was then added to the wells and incubated. After washing, a 
substrate solution was added and plates were incubated. The reaction was then stopped, and 
absorbance was read at 450 nm using plate reader (Synergy HT, BioTek Instruments Inc., 
Winooski, VT).  
Bone-specific alkaline phosphatase (BAP) 
Maternal plasma and infant serum bone-specific alkaline phosphatase (BAP), a marker of 
bone formation, was measured using an immunoenzymetric assay (Immunodiagnostic Systems 
(IDS) Inc. Gaithersburg, MD). Samples, standards, and controls were pipetted in a streptavidin 
coated 96-well plate and reacted with a solution containing a biotin labeled, BAP-specific 
monoclonal antibody. During incubation, an antibody/BAP complex was formed. Plates were 
then washed to remove unbound BAP and incubated with an enzyme substrate. The amount of 
substrate was determined by measuring absorbance at 405 nm in a 96-well plate reader (Synergy 
HT, BioTek Instruments Inc., Winooski, VT).  
 
Osteocalcin (OC) 
Maternal plasma osteocalcin (OC) activity was measured using ELISA kits 
(Immunodiagnostic Systems (IDS) Inc. Gaithersburg, MD). The assay uses two monoclonal 
antibodies against human osteocalcin. Samples, standards, and controls were pipetted into a 
streptavidin coated 96-well plate. A mixture of biotinylated and peroxidase conjugated antibody 
was then added to the micro wells. Following incubation, the wells were washed, and a 
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chromogenic substrate was added. Finally, the reaction was stopped with sulfuric acid and 
absorbance was measured at 405 nm with 650 nm as a reference in a 96-well plate reader 
(Synergy HT, BioTek Instruments Inc., Winooski, VT).  
Cross-linked telopeptide type 1 collagen (CTX)  
Maternal plasma C-terminal telopeptides of type 1 collagen (CTX) were determined 
using ELISA kits (Immunodiagnostic Systems (IDS) Inc. Gaithersburg, MD). The assay uses two 
monoclonal antibodies against an amino acid sequence where the aspartic acid residue is β-
isomerized. To be detected by the ELISA system, the two chains of the amino acids must be 
cross-linked. Samples, standards, and controls were pipetted in a streptavidin coated 96-well plate 
followed by addition of a mixture of biotinylated and peroxidase conjugated antibody. A complex 
of antigens and the two antibodies was formed which bound to the plates. Following incubation, 
the wells were washed, and a chromogenic substrate was added. The reaction was stopped with 
sulfuric acid and absorbance was measured at 405 nm with 650 nm as a reference in a 96-well 
plate reader (Synergy HT, BioTek Instruments Inc., Winooski, VT).  
 
Urinary Calcium, Phosphorous and Creatinine  
Maternal urinary creatinine, calcium and phosphorous were analyzed using a clinical 
chemistry analyzer (Carolina Liquid Chemistries Corp., Bera, California). The urinary creatinine 
assay uses a series of coupled enzymatic reactions. Creatinine is converted into creatine by the 
action of creatininase, which is then converted to sarcosine. Sarcosine is then oxidized to produce 
hydrogen peroxide. In the presence of peroxidase, hydrogen peroxide is quantified at 546 nm by 
the formation of a colored dye.  
The calcium method measures a colorimetric reaction in which calcium forms a complex 
with arsenazo III which produces a color. Absorbance is then read at 660 nm. The color intensity 
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is directly proportional to calcium concentration. To determine urinary phosphorus, it was reacted 
with ammonium molybdate and sulfuric acid forming a phosphomolybdate complex. Change in 
absorbance was measured at 340 nm.  
  Serum Albumin and Cholesterol  
Serum albumin was determined using the dye-binding property of albumin. Albumin 
reacts with bromocresol green (BCG) to form a green color. The intensity of the color is 
proportional to the quantity of albumin.The color change is measured at 600 nm. Serum 
cholesterol was determined enzymatically. Cholesterol esters were initially hydrolized to free 
cholesterol and fatty acids. Cholesterol was then oxidized into cholesterol-4-en-3-one and 
hydrogen peroxide. Peroxidase catalyzes the oxidative coupling of 4-aminoantipyrine with 3,4-
dichlor-2-hydroxybenzenesulfonic acid (DHBS) to form a dye which is read at 505 nm.  
Statistical Analysis 
Data were analyzed using SAS (Version 9.4, SAS Institute Inc., 2013) and IBM SPSS 
(version 23, 2016, IBM Corp.) Normality was tested using the one-sample Kolmogorov-Smirnov 
test. Variables that were skewed were transformed using log or square root transformation before 
analysis. Differences in 25(OH)D and bone markers between groups were tested using repeated 
measures ANOVA. An independent-sample t- test was used to test cross-sectional mean 
differences. The Mann-Whitney U test was used for non-parametric data (dietary data). Chi-square 
test was used to test proportion differences. Binomial regression analysis was performed to test 
differences in child illness incidences. Differences in the attainment of motor milestones between 
the two groups were tested using COX hazard ratios (Survival analysis). Statistical significance 
was set at P< 0.05. 
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Ethical Considerations  
Ethical clearance for the study was obtained from the Oklahoma State University 
Institutional Review Board, the Hawassa University Institutional Review Board and the Ethiopian 
National Health Research Ethics Review Committee. Final approval for implementation was 
provided by the Food, Medicine and Health Care Administration and Control Authority of 
Ethiopia (FMHACA).  
Safety Assessment and Monitoring  
There were no anticipated serious adverse events (SAE) associated with this intervention 
in which the vitamin D intake on a daily basis was half of the upper limit (RDA Reference) and 
much lower than studies that used doses up to five times higher (10,000 IU/day) and reported no 
adverse events. However to ensure the safety of study participants and because the study was 
considered as a drug trial for regulatory purposes, morbidity data and information on adverse 
events were collected weekly. The trial was also be overseen by a Data Safety Monitoring Board 
(DSMB). The DSMB had the responsibility to ensure the safety of study participants and the 
validity and integrity of data collected. The DSMB received quarterly reports and reviewed 
relevant data on serious adverse events, morbidity, study outcomes, enrollment and participant 
retention. No serious adverse events that can be attributed to the intervention occurred 
A written report was provided to the DSMB and FMHAC immediately after a serious 
adverse events (mortality or hospitalization) regardless of causality. The report contained a 
description of the event, date and time of onset, clinical history, associated signs and symptoms, 
temporal association with the study, medical management, severity, and causal relationship with 
the study intervention.
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CHAPTER IV 
 
 
VITAMIN D SUPPLEMENTATION OF ETHIOPIAN LACTATING MOTHERS IMPROVES 
MATERNAL PLASMA 25(OH)D BUT NOT INFANT 25(OH)D: A RANDOMIZED, 
DOUBLE- BLINDED, CONTROLLED TRIAL 
  
Abstract  
Background: Vitamin D is crucial for calcium and phosphorous homeostasis and bone health. 
Vitamin D insufficiency is prevalent in populations residing close to the equator despite abundant 
ultraviolet light (UVB). Response to vitamin D supplementation among lactating women and 
effect on infants in such settings are unknown. 
Objective: To evaluate the effects of vitamin D supplementation provided to lactating women for 
12 months on maternal and infant 25(OH)D and other markers of vitamin D status.  
Methods: We conducted a double-blind, randomized controlled trial in Sidama Zone (7oN, 38oE), 
Southern Ethiopia. Lactating women (n=126) enrolled within two weeks postpartum were 
randomized to receive weekly vitamin D3 (15,000 IU/week) or placebo. The primary outcome 
was change in plasma 25(OH)D. Plasma 25(OH)D concentration was determined using the new 
VDSP (Vitamin D Standardization Program)   
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certified Immunodiagnostic Systems (IDS) 25-hydroxy vitamin DS manual ELISA Kits. Data on 
demographic characteristics, dress habits and sun-seeking behavior were collected using 
questionnaires. Skin reflectance was measured using a portable color meter. UVB exposure was 
quantified using portable electronic dosimeters.  
Results: Median (IQR) 25(OH)D concentrations were not significantly different between vitamin 
D and placebo groups at baseline [45 (39, 56) vs 47 (37, 57) nmol/L, p=0.697]. Medain maternal 
25(OH)D was significantly higher in the vitamin D group at one year [109 (93, 121) vs 62 (50, 
81) nmol/L, p < 0.0001]. All women in the vitamin D group were vitamin D sufficient (> 50 
nmol/L) by the end of the study. Furthermore, 95% had attained 25(OH)D concentrations > 75 
nmol/L compared to 39% in the placebo group. Infant 25(OH)D concentrations at one year were 
not significantly different between groups (P = 0.974). 
Conclusions: Weekly Vitamin D3 (15,000 IU/week) supplementation safely eliminated vitamin D 
insufficiency in lactating women. The intervention did not produce a significant difference in 
infant 25(OH)D at 12 months. Trial registered at clinicaltrials.gov (NCT02210884).  
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Introduction  
Vitamin D is produced in the skin from 7-dehydrocholesterol by the action of ultraviolet 
light (UVB) and can be obtained from the diet1-3. Its main function is regulation of calcium and 
phosphorous homeostasis thus influencing mineralization of bone4. Possible non-calcemic 
function of vitamin D includes regulation of immune response and cell proliferation4-6. Vitamin D 
deficiency in adults leads to osteomalacia and is also associated with muscle weakness and 
osteoporosis2. In children, deficiency results in rickets and is linked to increased risk of 
respiratory infections and poor growth 7,8. Lactating women and infants are at an increased risk of 
vitamin D deficiency due to increased physiological needs 9,10. With a high rate of skeletal 
growth, infants meet their vitamin D needs mainly through breastmilk unless they are 
supplemented with vitamin D 9. However, breast milk has been shown to be low in vitamin D, 
which increases the risk of deficiency11. Maternal vitamin D deficiency and exclusive 
breastfeeding are commonly seen in infants with rickets 4. 
Regions located between 37O N and 37OS have adequate sunlight to maintain optimal 
concentrations of 25(OH)D throughout the year12,13. In some of these regions foods are not 
commonly fortified with vitamin D, so synthesis in the skin is a primary source. Despite adequate 
ambient UVB hypovitaminosis D has been reported in India14,15, Iran16 and Turkey17 among 
pregnant women and newborns and in the United Arab Emirates (UAE)18 among exclusively 
breastfed infants and lactating mothers. Vitamin D deficiency also has been reported in other 
target groups residing in countries with abundant sunshine19,20. Latitude, season, a conservative 
dress style limiting the amount of body surface area exposed to the sun, sunscreen use, and air 
pollution21 are some factors that affect the amount of UV light that reaches the surface of the skin 
hence reducing synthesis 2,22. Individuals with darker skin are at an increased risk of vitamin D 
deficiency because they have a higher level of melanin that acts as a UV filter22. The degree to 
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which these factors modulate response to vitamin D supplementation in such settings is not 
known.  
 Ethiopia is located near the equator and has abundant UVB throughout the year, which is 
the main source of vitamin D. A conservative dress style and cultural practices such as extended 
confinement after delivery limit sun exposure. Vitamin D insufficiency is prevalent in pregnant 
and non-pregnant women23,24 and adolescents25. Exclusive breastfeeding for the first months is 
widely practiced. Prenatal supplements mainly contain iron and are not widely consumed26. 
Infants are not supplemented with vitamin D. Determination of response to vitamin D 
supplementation can improve our understanding of vitamin D nutrition in similar settings. Thus, 
the aim of this study was to evaluate changes in maternal and infant vitamin D status in response 
to a weekly vitamin D supplement (15,000 IU) vs. placebo administered to lactating women.  
 
Methods 
Study setting  
The study was conducted from October 2014 to January 2016 in four rural communities 
(Alamura, Finchawa, Chefe Koti Jebesa, and Tullo) located near Hawassa town (7oN, 38oE), 
Southern Ethiopia. Subsistence farming is the main source of income for the study population. 
Maize (Zea maysL.) and enset (Enset ventricosum) are the main staple foods 27. A preliminary 
analysis of vitamin D status of women in the study area showed that 84% of the participants had 
25(OH)D concentrations below 50 nmol/L 24. Exclusive breastfeeding for the first six months of 
life is widely practiced (58%), and breastfeeding continues well after the first year with 91% of 
children aged 12-17 months currently breastfeeding in 2016 26. Foods are not fortified with 
vitamin D in the country. Ethiopia has UVB exposure adequate to produce sufficient vitamin D 
all year round.  
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Participants  
 Lactating women and infant dyads were enrolled in the study if they were apparently 
healthy, delivered within two weeks and were currently breastfeeding and planned to continue for 
12 months. Screened mothers were excluded if they had any self-reported chronic or acute 
disease condition (liver and kidney disease, diabetes, tuberculosis, or HIV), had twin births or 
were not permanent residents of the area.  
Study Design  
The study was a parallel group, double-blind, randomized, controlled vitamin D 
supplementation trial. Lactating women enrolled in the trial were randomized to one of the study 
arms and received 15,000 IU vitamin D3 or placebo capsules weekly for 12 months. 
Intervention  
Vitamin D and placebo (composed of plant fiber) tablets were formulated by Pure 
Encapsulations (Pure Encapsulations Inc., Sudbury,MA) and were identical in appearance. 
Community Research Workers (CRW) made weekly home visits and gave the intervention to the 
lactating women. To guarantee compliance mothers took the capsules while the CRW observed.  
 Simple randomization was used to randomly assign the study participants to one of the 
two intervention groups. The randomization sequence was generated using the website 
Randomization.com (http://www.randomization.com/ ) 28. The sequences with the corresponding 
codes were sealed in opaque envelopes that were sequentially numbered on the outside. When a 
mother met the screening criteria and gave informed consent, she was given an envelope that 
contained an allocation sequence. Envelopes were allocated to participants sequentially following 
the number on the outside of the envelopes. After assignment, the researcher (MG) opened the 
sealed envelope and recorded the mother’s intervention code in a separate master sheet. 
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Ethical clearance for the study was obtained from the Oklahoma State University 
Institutional Review Board, the Hawassa University Institutional Review Board, the Ethiopian 
National Health Research Ethics Review Committee and the Food, Medicine and Health Care 
Administration and Control Authority of Ethiopia (FMHACA). The trial was registered at 
clinicaltrials.gov (Registration number: NCT02210884). Study participants provided an informed 
written consent before enrollment.  
Outcome assessment  
Laboratory analysis  
Maternal venous blood samples were collected at baseline, 6 and 12 months using lithium 
heparin coated tubes (Sarstedt, Inc., Newton, NC.). Infant venous blood samples were collected at 
end-line. All blood samples were non-fasting. Blood samples were centrifuged at 2000 x g for 10 
minutes at room temperature to separate plasma from red blood cells. Maternal spot urine 
samples were collected at 3, 6, and 12 months. All samples were stored at -15 to -20 OC at 
Hawassa University before shipment (in dry ice) to Oklahoma State University for further 
analysis. 
Total plasma 25(OH)D concentration was determined using VDSP (Vitamin D 
Standardization Program) certified Immunodiagnostic Systems (IDS) 25-Hydroxy Vitamin DS 
EIA manual ELISA Kits. To maintain maximum assay performance our lab participated in the 
CDC Vitamin D Standardization Certification Program (VDSCP)29. As part of the standardization 
program, seven external quality control materials were run along with samples in each ELISA 
plate. These control materials were obtained from the National Institute of Standards and 
Technology (NIST), and the VDSP program. No significant bias (average deviation from a true 
value) was noted for quality control samples across all plates. The individual sample bias ranged 
from -8.9% to 15.0%. The imprecision (CV) from the replicate measurements was within 
suggested criteria of <10% across all seven samples (range 2.4-7.7%). 
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Maternal parathyroid hormone (PTH) concentrations were measured in plasma using 
Immutopics ELISA kits (Immutopics Inc, San Clemente, CA). Urinary creatinine, calcium, 
phosphorous and serum albumin and cholesterol were analyzed using a clinical chemistry 
analyzer (Carolina Liquid Chemistries Corp., Bera, CA).  
Determination of Skin pigmentation  
Skin reflectance (pigmentation) was measured at three different locations (middle of the 
upper inner arm, outer hand, and in the middle of the forehead) using a portable ColorTec 
PCM+TM color meter (ColorTec Associates, Inc., Clinton, NJ). Measurements were expressed 
using the International Commission on Illumination (CIE) LAB color space ( L* (black to white), 
a* (red to green) and b* (yellow to blue). L* indicates skin lightness and values can range from 0 
to 100. Zero indicated perfect black and 100 indicated perfect white30. L* values were used as a 
marker for skin pigmentation in this study. 
 
Ultraviolet (UVB) Exposure  
Individual maternal personal UVB exposure was measured using personal electronic 
dosimeters after end-line assessment. The dosimeters measure UVB irradiance at 8-second 
intervals, which is converted to erythemally-weighted standard erythema dose (SED). One SED is 
equivalent to an erythemal effective radiant exposure of 100 J/m2. SED provides a measure of 
UVB exposure independent of skin type. The electronic dosimeters were placed on participant’s 
outer wrist (like a watch) for five days. Clothing worn during this time was assessed using 
questionnaires to estimate the portion of body surface area exposed to UVB. Usual SED exposure 
was calculated by taking the average of daily SED values. SED values were adjusted for body 
surface area exposed BSAE. 
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Anthropometric assessment and Questionnaires  
Maternal height and weight and, infant weight and length were measured using 
standardized techniques 31 and calibrated equipment. Trained research assistants administered 
questionnaires to mothers in the local language. The questionnaires were used to assess 
demographics, socioeconomic status, and infant and maternal sun exposure behavior and dress 
habits. Percent BSAE was calculated from clothing data collected using a modified version of the 
rule of nines used for burn assessment 32. 
Sample size  
The primary endpoint of this study was to assess mean differences in 25(OH)D 
concentrations between the two study groups (placebo and Vitamin D). Hence sample size was 
estimated for a repeated measure, between factors ANOVA test using the software G*Power 
version 3.0.10 (Franz Faul, Kiel University, Kiel, Germany). A sample size of 108 was calculated 
to be adequate using a small effect size of 0.25, a 0.05 level of significance and 90% power. After 
a 15% adjustment for a possible loss to follow-up, the final sample size for the study was 126 (63 
in each group).    
Statistical analysis 
Data collected were analyzed using SAS (Version 9.4, SAS Institute Inc., 2013) and IBM 
SPSS (version 23, 2016, IBM Corp.) Normality was tested using the one-sample Kolmogorov-
Smirnov test. Variables that were not normally distributed were transformed using log (25(OH)D) 
or square root (PTH) transformation before analysis. Predictors of 25(OH)D at baseline were 
determined using linear regression. Differences in 25(OH)D and other biochemical outcomes 
between groups were tested using repeated measures ANOVA. An independent-sample t- test was 
used to test cross-sectional mean differences. Chi-square test and Fisher's exact tests were used to 
test proportion differences. Statistical significance was set at P< 0.05. 
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Results  
A total of 152 mother-infant pairs were assessed for eligibility. Of those screened the 
eligible 126 women were randomized into either the vitamin D (n=63) or placebo (n=63) groups. 
Of those randomized 11 were lost to follow-up. Reasons for discontinuation were moving away 
(n=6), infant death (n=2), pregnancy (n=1) and withdrawal of consent (n=2) (Figure 3.1). Eleven 
of women in the Vitamin D and 9% in the placebo group were lost to follow-up. Total 
compliance (proportion of capsules consumed to distributed) was 99%. The vitamin D group had 
99.2% compliance, and the placebo group had 99% compliance. Eighty-one percent of the 
mothers were 100% compliant. More than half 60% of the mothers reported that they avoided 
going outside the home for 4 weeks after delivery. However, 97% of mothers reported that they 
expose newborns to the sun during the first 12 weeks after birth.  
Maternal and infant characteristics were similar between groups at baseline (Table 4.1). 
Maternal 25(OH)D concentrations were not significantly different between the vitamin D (44.9 
nmol/L) and placebo (46.9 nmol/L) group (P = 0.697). The majority of mothers in both groups 
were vitamin D insufficient using the Institute of Medicine (IOM) cutoffs33 (58% in placebo 
group and 59 % in Vitamin D group). Age (P< 0.001) and weight (P= 0.02) were significant 
predictors of maternal 25(OH) D concentrations at baseline (Table 4.2). Percent BSAE exposed 
did not significantly predict 25(OH)D concentrations (P = 0.625, R2 = 14.2%). Skin lightness was 
positively correlated with 25(OH)D ( r = 0.176, P = 0.06, ). However, it did not predict 25(OH)D 
in a multivariate regression model (P = 0.151, R2 = 14.2%).  
Changes in maternal 25(OH)D concentrations over time are shown in Figure 4.1. 
Supplementation with Vitamin D3 had a substantial significant effect on maternal vitamin D 
status at six months and end-line. At six months, median (IQR) maternal 25(OH) D 
concentrations were 121 (91, 147) in the vitamin D group compared to 65 (57,79) in the placebo 
group ( P < 0.001).The 25(OH)D concentrations declined at end-line in the vitamin D group 
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compared to the values at six month 109 (93, 121) (p= 0.003 ). However, values were still 
significantly higher compared to the placebo group (63 (49, 81), P < 0.001). In the placebo group 
25(OH)D concentrations increased significantly at six months compared to baseline (P < 0.001) 
which was expected since baseline assessment was carried out towards the end of the rainy 
season where 25(OH)D levels will be at their lowest. Furthermore maternal activity outside the 
home is likely to be limited towards the end of pregnancy. No change was seen from 6 months to 
end-line. All lactating women in the Vitamin D group were vitamin D sufficient ( > 50 nmol/L) at 
six months and 12 months ( Table 4.3). In contrast, 15.3% and 23.8 % of mothers in the placebo 
group were insufficient at 6 and 12 months respectively. Controlling for baseline 25(OH)D, 
maternal weight (p= 0.227), maternal age (p= 0.490), skin lightness (P=0.412), and PTH 
(P=0.361) did not modify the effect of vitamin D supplementation on end- line 25(OH)D. Infant 
25(OH)D concentrations at end-line ranged from 44.3 to 170 nmol/L in the placebo group and 
60.2 to 174 nmol/L in the Vitamin D group. There was no statistically significant difference in 
infant 25(OH)D by treatment group (p = 0.974).  
Serum PTH increased at end-line compared to baseline in both groups (Table 4.4). PTH 
concentrations were negatively correlated with 25(OH)D concentrations (Figure 4.2).Median 
(IQR) urinary calcium to creatinine ratio remained similar between the two groups over time. 
Furthermore, there was no significant difference in the proportion of mother with ratios > 0.7 and 
> 0.14 in either group. In the vitamin D group urinary phosphorous significantly increased over 
time (P= 0.013). Unadjusted UVB and adjusted UVB exposure (adjusted for body surface area 
exposed) measured as standard erythema dose (SED) did not significantly differ between the two 
groups (P = 0.466) (Table 4.5).  
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 Discussion  
This study aimed to examine the effect of long-term maternal vitamin D3 
supplementation (15,000 IU/week) during lactation on maternal and infant 25(OH)D 
concentrations. Supplementation significantly raised maternal plasma 25(OH)D concentrations at 
6 and 12 months (end-line). However, we did not see significant differences in infant 25(OH)D 
concentration between the vitamin D and placebo groups at end-line. All the women and infants 
in the vitamin D group were vitamin D sufficient using the IOM cut-off for sufficiency (50 
nmol/L)33. This study provides data on response to vitamin D supplementation relevant for setting 
with abundant UVB exposure, variable sun exposure, and darker skin pigmentation.  
  The present findings build on work done by Saadi et al. among women in the United 
Arab Emirates. Saddi and colleagues supplemented 90 lactating women from 1-month post-
partum to 3 months with 2000 IU vitamin D2/ week or 60,000 IU vitamin D2/ month. Infants 
received 400 IU vitamin D2/week 18,34. Baseline mean 25(OH)D concentrations were 27 nmol/L 
(weekly group) and 23 nmol/L (monthly) compared to 48 nmol/L in both groups in our study34. 
At 3 months maternal 25(OH)D concentrations changed (from baseline) from 27 to 42 nmol/L in 
the weekly group and 23 to 28 nmol/L in the monthly group34. Infant 25(OH)D was raised 14 to 
50 nmol/L in the weekly group and 14 to 45 nmol/L in the monthly group18. Mean increment in 
maternal 25(OH) was lower compared to our study. The change we saw in maternal 25(OH)D is 
closer to the response to supplementation reported by Hollis35,36, and Basile37 for lactating women 
in South Carolina. In their most recent, study Hollis et al.38 evaluated response to two doses of 
vitamin D3: 400 IU/day, and 6400 IU/day in lactating women (for 6 months). Infants in the 400 
IU group were supplemented with 400 IU vitamin D3/day. Maternal mean 25(OH)D 
concentrations at visit 1 and end-line were 89 and 79 nmol/L in the 400 IU group and 99 and 151 
nmol/L in the 6400 IU group (an increase of -10 and 52 nmol/L respectively).  
 Based on equations derived by Heaney et al.39 we can expect that serum 25(OH)D 
concentrations will increase by 0.7 – 1.0 nmol/L per 1 µg (40 IU) daily intake of vitamin D. 
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Accordingly, for the dose we provided, an increase in the 37 to 64 nmol/L range is reasonable. 
The increase we saw in the vitamin D group ( 60-75 nmol/L) in our study corresponds to the 
widely used Heaney et al39, adult estimates, especially when we take into account the increase in 
the placebo group (19-22 nmol/L). Our changes were similar to changes seen by Hollis38 for a 
6400 IU vitamin D3/day dose and 5000 IU vitamin D3/day for women in the US34. However, 
direct comparisons between our study and these two studies may not be appropriate due to 
differences in availability of ambient UVB, dress habits and differences in dietary vitamin D 
intakes.  
Interestingly contrary to what has been reported by other studies38,40,41 maternal 
supplementation did not result in a significantly higher infant 25(OH)D compared to placebo. At 
end-line 98% of infants in the placebo group were vitamin D sufficient. Several factors might 
explain our results. The duration of intervention in other studies ranged from 28 days to 6 months. 
Our intervention was provided for 12 months, and infant 25(OH)D was assessed at 12 months. It 
is possible that we might have been able to detect a difference if outcome was assessed earlier in 
the study, since infant sun exposure increases with age. Our findings also suggest that sun 
exposure in Ethiopian infants maybe higher compared to other countries.  
This study is the first to characterize biochemical response to vitamin D3 supplementation 
(15,000 IU/week) among lactating women and their infants living close to the equator. However, 
this study had several limitations. We measured infant 25(OH)D concentrations only at end-line 
consequently we cannot make comparisons with baseline 25(OH)D. Furthermore, the inclusion of 
only one assessment time point prevents us from evaluating change over time. We also did not 
quantify UVB exposure among infants. Future studies should quantify vitamin D synthesis 
through this exposure. Moreover, breastmilk vitamin D concentrations should also be measured to 
determine how much benefit is transferred to infants. The World Health Organization (WHO) sets 
nutrient intake recommendations for the global population. Its current RDA for vitamin D is 200 
IU per day. These recommendations have not been updated since 2004 and the WHO has stated 
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that more research is needed to update recommendations, especially with regards to the role of 
vitamin D in infant respiratory health and benefit during pregnancy42. Thus future studies should 
assess effect of supplementation on maternal and infant health outcomes in UVB abundant 
locations.  
 
Conclusion  
In conclusion, in a population residing closer to the equator with darker skin 
pigmentation, long-term oral maternal vitamin D supplementation significantly and safely 
improved maternal vitamin D status. The intervention did not produce significantly different 
improvements in infant vitamin D status.  
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Table 4.1 Baseline Characteristics of lactating women and infants, Southern Ethiopia 2014  
 
  Placebo 
(n= 59) 
Vitamin D   
 (n= 56) 
P-value 
Maternal Age (years)1 25 (20,30) 26 (20, 30) 0.469 
Weight (kg)2 54.2 + 7.4  53.3 + 7.3 0.734 
Height (m) 1.59 + 0.06 1.57 + 0.06 0.422 
Infant weight (kg) 3.3 + 0.5 3.4 + 0.5 0.880 
Infant sex ratio (M:F) 1.1 1.3 0.680 
Skin lightness (*L) 34.1 + 3.5  34.0 + 3.2 0.647 
Body surface area exposed (BSAE) 0.23 (0.16, 0.28) 0.24 (0.20, 0.29) 0.802 
Maternal 25(OH)D nmol/L 44.9 (38.5,55.6) 46.9 (37.2,57.1) 0.697 
PTH (pg/mL)1 54.7 (35.0, 86.3) 50.7 (35.0, 76.4) 0.381 
Number of pregnancies 3    
   Primiparous  23.0 (39.0) 22.0 (39.3)  
   Multiparous 36.0 (61.0) 34.0 (60.7) 0.937 
Maternal education     
   No formal education  23.0 (39.0) 16.0 (28.6)  
   Primary education  30.0 (50.8) 31.0 (55.4) 0.407 
   Secondary education or higher  6.0 (10.2) 9.0 (16.0)  
Maternal occupation     
   Housewife 51 (86.4) 47 (83.9)  
   Employed outside the house  1 (1.7) 3 (5.3) 0.683 
   Petty trading 7 (11.9) 6 (10.7)  
1 Median (25th percentile, 75th percentile) (all such values) 2 Mean + SD (all such values)3 n(%) 
(all such values). PTH: Parathyroid hormone.  
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Table 4.2. Predictors of maternal 25(OH)D concentrations at baseline (n= 115), Southern 
Ethiopia 2014   
 
 
 
 
 
 
 
 
 
   
β 
95 % CI for  β  
P-value  Lower  Upper  
Maternal age -0.741 -1.149 -0.334 0.001 
Maternal weight  -0.386 -0.713 -0.059 0.021 
Skin Lightness (L*) 0.539 -0.199 1.277 0.151 
BSAE -10.36 -52.4 - 31.6 0.625 
 Adj. R2 0.142 
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Figure 4.1. A) Significant group and time 
differences were observed (P< 0.001). Error bars 
indicate 25th and 75th percentiles. B) & C) Box-
and-whiskers plots. Vertical line inside boxes 
indicates the median. Ends of boxes indicate the 
first and third quarters. Whiskers show highest 
and lowest observations. C) No significant 
differences seen between groups (P = 0.975). 
Southern Ethiopia 2014 -2015. 
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Table 4.3. Maternal and infant plasma 25(OH)D categorical distributions by supplementation 
group, Southern Ethiopia 2014 - 2015 
 Placebo Vitamin D  p value 
Materanl 25(OH)D concentrations baseline 1 0.738 
 < 30 nmol/L 2 (3.4) 3 (5.4)  
30 – 49 nmol/L 32 (54.2) 30 (53.6)  
50-75 nmol/L 20 (33.9) 21 (37.5)  
> 75 nmol/L 5 (8.5) 2 (3.6)  
Maternal 25(OH)D concentrations 6 months  < 0.001 
 < 30 nmol/L 0 0  
30 – 49 nmol/L 9 (15.3) 0  
50-75 nmol/L 31 (52.3) 2 (3.6)  
> 75 nmol/L 19 (32.2) 54 (96.4)  
Maternal 25(OH)D concentrations 12 months < 0.001 
 < 30 nmol/L 0 0  
30 – 49 nmol/L 14 (23.7) 0  
50-75 nmol/L 22 (37) 3 (5.4)  
> 75 nmol/L 23 (39) 53 (94.6)  
Infant 25(OH)D concentrations infants    0.933 
 < 30 nmol/L 0 0  
30 – 49 nmol/L 1 (1.7) 0  
50-75 nmol/L 5 (8.5) 4 (7.1)  
> 75 nmol/L 53 (89.8) 52 (92.8)  
      1 n(%) (all such values), Chi- square test or Fischer’s exact test  
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Table 4.4. Calcium and vitamin D status markers by supplementation group, Southern Ethiopia 2014 - 2015  
 n Placebo n Vitamin D  p value 
     Group  time Group by time  
Urinary Ca/Cr ratio1     0.586 0.756 0.322 
3 months 58 0.003 (0.001, 0.008) 54 0.008 (0.002, 0.024)    
6 months 58 0.006 (0.002, 0.021) 55 0.007 (0.002, 0.022)    
12 months  59 0.011 (0.007, 0.027) 56 0.014 (0.007, 0.032)    
Urinary calcium (mg/dL)     0.973 0.016 0.235 
 3 months 58 0.2 (0.1, 0.6) 55 0.5 (0.1, 1.0)    
6 months 59 0.5 (0.2, 1.2) 55 0.5 (0.2, 1.2)    
12 months  59 0.8 (0.4, 2) 56 1.0 (0.6,2.0)    
Urinary Creatinine (mg/dL)     0.571 0.001 0.684 
 3 months 58 62.7 (43.9, 92.5) 54 58.2 (39.1, 77.3)    
6 months 58 74.2 (43.8, 103) 55 68.5 (51.6, 98.8)    
12 months  59 70.8 (46.4, 114.8) 56 62.4 (53.0, 101.0)    
Urinary phosphorus (mg/dL)      0.801 0.001 0.013 
3 months 58 16.2 (3.4, 24.1) 55 9.8 (4.3, 24)    
6 months 59 19.5 (6.6, 26.6) 54 16.5 (7.2, 24.9)    
12 months  59 15.2 (9.4, 36.4) 56 29.2 (13, 44.3)    
Albumin (g/dL)     0.060 0.000 0.925 
Baseline  59 3.3 (2.7,3.6) 56 3.3 (2.9, 3.7)    
3 months 59 3.9 (3.4,4.4) 56 4.1 (3.5, 4.6)    
6 months 49 3.7 (3.3,3.9) 48 3.8 (3.3, 4.1)    
12 months  58 3.8 (3.4, 4.3) 56 3.9 (3.5, 4.2)    
PTH (pg/mL)     0.463 0.014 0.331 
Baseline  59 54.5 (34.7, 85.1) 56 50.7 (35.0, 76.4)    
12 months 59 57.9 (45.3, 84.4) 56 61.2 (42.9, 82.6)    
11 Median (25th percentile, 75th percentile)  
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A) Placebo                                                        B) Vitamin D  
                       
Figure 4.2. Correlation between maternal PTH (pg/mL) and 25(OH)D (nmol/L) at baseline, Southern Ethiopia 2014 - 2015  
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C) Placebo                                                                                                                                    D) Vitamin D  
             
Figure 4.3. Correlation between maternal PTH (pg/mL) and 25(OH)D (nmol/L) at end-line, Southern Ethiopia 2014 - 2015 
r=-0.249, P=0.69 r=-0.220, P= 0.100 
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    Table 4.5. Usual UVB exposure (SED) by supplementation group, Southern Ethiopia 2015 
 Placebo Vitamin D p value 
Usual UVB (SED)1 2.0 (1.1, 3.0) 1.7 (0.7. 3.0) 
 
0.466 
Adjusted usual UVB (Adj. SED)2 0.43 (0.22, 0.73) 0.37 (0.17, 0.77) 0.593 
     1 Median (25th percentile, 75th percentile), Mann-Whitney U test. 2 Adjusted for Body Surface Area Exposed (BSAE), SED: 
Standard erythemal dose  
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CHAPTER V 
 
 
EFFECTS OF VITAMIN D SUPPLEMENTATION ON MARKERS OF BONE TURNOVER 
IN LACTATING WOMEN AND THEIR INFANTS: A 12 MONTHS RANDOMIZED, 
DOUBLE- BLIND, CONTROLLED TRIAL  
Abstract  
Background: Vitamin D is crucial for calcium and phosphorous homeostasis and bone health. No 
study has evaluated whether vitamin D supplementation alters skeletal resorption during lactation, 
in women with marginal to low dietary calcium intakes. 
Objective: To evaluate the effect of a vitamin D3 vs. placebo supplement provided to lactating 
women from 2 weeks after delivery for 12 months on maternal and infant markers of bone 
turnover.  
Methods: We conducted a double-blind, randomized controlled trial in Sidama Zone (7o N, 38o 
E), Southern Ethiopia. Lactating women (n=126) enrolled within two weeks postpartum were 
randomized to receive weekly vitamin D3 (15,000 IU/week) or placebo for 12 months. Plasma 
25(OH)D, bone-specific alkaline phosphatase (BAP), C-terminal telopeptides of type 1 collagen 
(CTX), Osteocalcin (OC), and parathyroid hormone (PTH) concentrations were measured using 
ELISA kits. Dietary intake was assessed using weighed food records at three months post-partum. 
Differences in bone turnover markers were tested using repeated measures ANOVA. 
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Results: Bone turnover markers and PTH were not significantly different between vitamin D and 
placebo groups at baseline. At baseline, OC was significantly higher in participants who were 
vitamin D sufficient (> 50 nmol/L) compared to those participants who were vitamin D 
insufficient ( P = 0.004). There was no significant difference change in bone markers in the 
vitamin D group compared to placebo. Bone formation markers OC (P = 0.006) and BAP (p = 
0.018) were significantly higher at end-line in both groups. Infant BAP was numerically higher in 
the vitamin D group at end-line (p =0.128) 
Conclusions: Vitamin D supplementation did not significantly influence bone turnover markers 
in African women with low habitual dietary calcium intake. Trial registered at clinicaltrials.gov 
(NCT02210884).  
 
Introduction  
Vitamin D is essential for calcium homeostasis and bone health. Deficiency is known to 
cause osteomalacia in adults and rickets in children2. Bone is constantly being remodeled and is 
thus highly metabolically active89. Lactation is a highly bone catabolic life stage. Lactating 
women lose up to 10% of their bone mineral density to provide sufficient calcium in breast milk 
for the rapidly growing infant84,110. A lactating mother provides 200-300 mg of calcium in a day 
to the infant84,110,111. These physiological changes are coupled with changes in bone turnover 
markers. These markers are of interest since they have a potential to predict osteoporosis and 
fracture risk87. Both markers of bone formation and bone resorption are elevated during lactation 
indicating high bone metabolic activity90. Furthermore, ionized calcium levels are reported to be 
slightly higher, serum phosphate levels are elevated, and parathyroid hormone (PTH) and 
calcitriol concentrations are lower78,111. Bone resorption during lactation is mainly directed by 
increased secretion of parathyroid hormone-related protein (PTHrp) during nursing and reduced 
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estradiol secretion84. Several studies have reported that bone loss during lactation is reversed after 
weaning and has no residual effect on long-term maternal bone health83,110,112. 
However, changes in some biomarkers are not universal to all women and can differ by 
race and dietary calcium intake and breastfeeding duration. Several studies have reported elevated 
PTH concentrations, and resistance to PTH stimulated bone resorption in African Americans and 
South Asians 86,113-115. In Gambian lactating women with habitually low dietary calcium intake 
PTH and calcitriol levels were elevated at 1 month post-partum and increased as lactation 
progressed86 suggesting atypical physiological responses to lactation. 
 Ethiopian women commonly breastfeed until a child is two years old. In the most recent 
demographic and health survey 85% of children age 12-23 months and 76% aged 20-23 months 
were still breastfeeding98. Additionally, the diet is low in calcium with a median (IQR) intake of 
479 (220, 680) mg/day reported for pregnant women in the study area50. The interval between 
pregnancies is short, and fertility rate is high. In a study that evaluated response to lactation in 
Gambian women that had similar characteristics to our study population, lactating women had 
lower BMD compared to Caucasians at 1-year post-partum116. The lower BMD in these Gambian 
women is contrary to the findings of studies that have reported higher BMD in African 
Americans despite low 25(OH)D and high PTH concentrations compared to caucasians113,114.  
The Institute of Medicine (IOM) classifies 25(OH)D concentrations < 50 nmol/L as 
inadequate for bone and overall health 11 25(OH)D concentrations below 30 nmol/L are 
associated with rickets and ostomalacia11. Studies that have measured vitamin D in Ethiopian 
women have shown that vitamin D insufficiency and deficiency are prevalent 36,38,117. Vitamin D 
status may influence the physiological adaptation to meet calcium needs during lactation. This 
combined with low dietary calcium intake and long-term exposure to bone loss due to repeated 
pregnancy can compromise bone health in this population. To our knowledge, no study has 
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evaluated whether vitamin D supplementation alters bone resorption during lactation, in women 
with marginal to low dietary calcium intakes. Thus the aim of this study is to assess the effect of 
vitamin D supplementation on markers of bone turnover in a population that has low calcium 
intake and prolonged lactation.  
Methods  
 
Participants & settings  
 Lactating women and their infants residing in Alamura, Finchawa, Chefe Koti 
Jebesa, and Tullo, located near Hawassa town (7oN, 38oE), Southern Ethiopia were enrolled in the 
study from October 2014 to January 2016. The women were eligible for enrollment if they 
delivered in the past two weeks, were breastfeeding at the time of enrollment and were apparently 
healthy. The study area is characterized by a reliance on subsistence farming as a main source of 
income. Maize (Zea maysL.) and enset (Enset ventricosum) are staple foods.  
Study Design and intervention  
The study was a parallel group, double-blind, randomized, controlled vitamin D 
supplementation trial. Lactating women enrolled within two weeks after delivery were 
randomized to one of the study groups and received either 15,000 IU vitamin D3 or Placebo 
capsules weekly for 12 months. Ethical clearance for the study was obtained from the Oklahoma 
State University Institutional Review Board, the Hawassa University Institutional Review Board, 
and the Ethiopian National Health Research Ethics Review Committee and the Food, Medicine 
and Health Care Administration and Control Authority of Ethiopia (FMHACA). The trial was 
registered at clinicaltrials.gov (Registration number: NCT02210884). 
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Outcome measures  
Laboratory methods  
Non-fasting venous blood samples were collected using Lithium Heparin coated tubes 
(Sarstedt, Inc., Newton, NC.). Infant blood samples were collected only at end-line (12 months). 
Blood samples were centrifuged at 2000 x g for 10 minutes at room temperature to separate 
plasma from red blood cells. Samples were stored at -15 to -20 OC at Hawassa University before 
shipment (in dry ice) to Oklahoma State University for further analysis. Maternal bone turnover 
markers were analyzed at baseline and end-line. 
Maternal and infant plasma bone-specific alkaline phosphatase (BAP), a marker of bone 
formation, was measured using EIA immunoenzymetric assay (Immunodiagnostic Systems (IDS) 
Inc. Gaithersburg, MD). Maternal plasma osteocalcin (OC) activity, a marker for formation, was 
measured using ELISA kits (Immunodiagnostic Systems (IDS) Inc. Gaithersburg, MD). The bone 
resorption marker cross-linked telopeptide type 1 collagen (CTX) was determined in maternal 
plasma using ELISA kits (Immunodiagnostic Systems (IDS) Inc. Gaithersburg, MD). Maternal 
intact parathyroid hormone (PTH) concentrations were measured in plasma using Immutopics 
ELISA kits ( Immutopics Inc, San Clemente, CA). The kit measures activity of intact PTH (PTH 
1-84). Total plasma 25(OH)D concentration was determined using the new VDSP (Vitamin D 
Standardization Program) certified Immunodiagnostic Systems (IDS) 25-Hydroxy Vitamin DS 
EIA manual ELISA Kits. 
Assessment of rickets  
At end-line, a pediatrician screened the infants for clinical signs of rickets. Signs that 
were examined were delayed fontanel closure, wrist widening, rachitic rosary, double malleoli, 
bow legs, ping-pong sensation on the skull (craniotabes), and delayed teeth eruption or dental 
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abnormalities. The pediatrician made a clinical diagnosis based on the presence of a combination 
of two or more symptoms.  
Dietary intake assessment  
At 3 months follow up a one day weighed food record was taken to assess dietary intake 
of all participants. Weekdays and weekends were represented in order to account for any day-of-
the-week effects. A diet worker stayed in a participant’s home from 6 am to 7 pm and measured 
and recorded every food and beverage consumed during the day using a digital weighing scale 
(Model CS 2000, Ohaus Corporation, USA). The Ethiopian Food Composition Table Part III and 
Part IV were used to calculate nutrient intakes using Food processor (Version 8.1, ESHA 
Research Inc, Salem, OR).  
Anthropometric assessment and Questionnaires  
Maternal height and weight, infant weight and length were measured using standardized 
techniques 100 and calibrated equipment. Trained research assistants administered questionnaires 
to mothers in the local language. The questionnaires were used to assess demographics, 
socioeconomic status.  
Statistical analysis 
A sample size of 108 was calculated to be adequate to test mean differences in outcome 
variables, using a small effect size of 0.25, a 0.05 level of significance and 90% power. After a 
15% adjustment for a possible loss to follow-up, the final sample size for the study was 126 (63 
in each group). Normality of continuous variables was tested using the one-sample Kolmogorov-
Smirnov test. Data was presented as mean (SD) and median (IQR). Variables that are not 
normally distributed were transformed using log or square root transformation. Baseline 
predictors of bone markers were tested using linear regression. Differences in bone turnover 
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markers were tested using repeated measures ANOVA. An independent-sample t- test was used 
to test cross-sectional mean differences. Mann-Whitney U test was used for non-parametric data 
(Dietary data). Statistical significance was set at P< 0.05. Data were analyzed using SAS (Version 
9.4, SAS Institute Inc., 2013) and IBM SPSS (version 23, 2016, IBM Corp.) 
 
Results  
Baseline characteristics of participants  
Participant flow through the trial has been reported elsewhere (Figure 3.1). Maternal 
haracteristics and bone markers at baseline were not significantly different between the vitamin D 
and placebo groups (Table 5.1). Mean maternal age at enrollment was 26 years and number of 
days postpartum ranged from 1 to 15 days. A majority of the lactating women initiated 
breastfeeding (94 %) immediately after birth. All women (100%) were still breastfeeding at end-
line and 90% were breastfeeding up to 7-9 times in a day. At baseline median OC concentrations 
were significantly higher in women who were vitamin D sufficient (> 50 nmol /L) compared to 
those who were insufficient (< 50 nmol/L) (P = 0.004) (Table 5.2). BAP concentrations were 
higher in vitamin D sufficient women and PTH was lower in Vitamin D deficient women (Table 
5.3). A unit increase in 25(OH)D was associated with a 0.004 increase in OC in a model that 
included age and days post-partum (P = 0.01, Adj. R2 = 0.221). 25(OH)D was significantly 
negatively correlated with the ratio of CTX to OC (CTX:OC) (r= -0.197, P = 0.037). BAP 
positively correlated with 25(OH)D (r=0.19, P= 0.044) and negatively with age (r = -0.248, P = 
0.008). Median (IQR) dietary intake at 3 months post-partum was 624 (389, 884) mg/day and 
calcium intake was not statistically different between the two groups (P = 0.52) (Table 5.4).  
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Effect of vitamin D supplementation  
 Bone formation and bone resorption markers were positively correlated at baseline and 
end-line. PTH was negatively correlated with both formation and resorption markers. Infant end-
line BAP was positively correlated with maternal end-line BAP and OC (Table 5).  
There was no significant difference in maternal BAP, OC, CTX, and PTH by 
supplementation group. Vitamin D supplementation did not significantly affect maternal and 
infant bone turnover markers. Maternal bone formation markers OC and BAP were significantly 
higher at end-line compared to baseline in both groups (P = 0.006 and P = 0.018 respectively). 
PTH was also significantly higher at end-line compared to baseline in mothers. However, this 
relationship disappeared when controlling for maternal age. Percent change in 25(OH)D did not 
predict percent change in maternal BAP, OC, CTX and PTH. Infant BAP was numericaly higher 
in the Vitamin D group compared to placebo (P = 0.128). Infant BAP was significantly correlated 
with age (r = 0.298, P < 0.001) but was not significantly correlated with height velocity (r = - 
0.046). Infants who had clinical signs of rickets had a higher mean BAP concentration compared 
with those with no signs of rickets [51.6 (20.5) vs. 46.8 (20.9)].  
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Discussion  
Among lactating women with relatively low dietary calcium intake, maternal vitamin D3 
supplementation (15,000 IU/week) for 12 months did not significantly influence bone turnover 
markers OC, BAP, CTX, and PTH. Bone formation markers were significantly higher at end-line 
in both the vitamin D and placebo groups. Supplementation did not result in PTH suppression in 
the study participants. Infant BAP concentrations were slightly higher in the vitamin D group. 
This study provides information on the effect of vitamin D supplementation on markers of bone 
turnover in lactating East African women, with limited dietary calcium intake for whom no data 
exist.  
  Similar to our findings, vitamin D supplementation did not affect bone turnover markers 
in studies done among Irish adult men and women, 23 Austrian hypertensive patients 24 and 
healthy Irish young and elderly adults 25. This finding support existing evidence that maternal 
physiological adaptations during pregnancy and lactation enable mothers to meet needs despite 
marginal intakes of calcium and vitamin D intakes 4,26. Another factor that might explain the lack 
of benefit is that baseline 25(OH)D concentrations were closer to sufficiency (46 nmol/L) in our 
study, and very few participants had values < 30 nmol/L. More benefit might have been observed 
if more participants had baseline 25(OH)D concentrations below 25 nmol/L which have been 
linked with bone disease18. 
Our findings build on work carried out by Prentice13 and Sawo27 that characterized 
longitudinal changes in biochemical markers of bone metabolism and bone mineral content in 
African lactating women, with low habitual dietary calcium intake. Prentice et al13. supplemented 
60 Gambian lactating women with calcium (714 mg/day) for 6 months post-partum and assessed 
changes in bone metabolism markers at baseline, 13 weeks and 6 months after supplementation 
stopped (at 52 weeks). Similar to our findings PTH levels increased during lactation compared to 
baseline. Osteocalcin and BAP levels also increased during lactation in both groups, although the 
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increase was slight for BAP. In 2015, Madar et al.28 supplemented 251 immigrants (from Sub-
Saharan Africa, South Asia, Middle East and North Africa) in Norway with either 400 IU, 1000 
IU vitamin D3/day or placebo for 16 weeks. Supplementation did not affect bone markers 
including CTX despite an increase in 25(OH)D. Supplementation however suppressed PTH 
levels. In our study supplementation did not suppress PTH levels. Furthermore, the increase in 
PTH did not result in a significant corresponding increase in CTX. The elevated PTH 
concentrations in our study population is similar to what has been reported for lactating African 
American women29 and African-Americans in general11,30,31. 
We saw a positive correlation between bone formation and bone resorption markers 
which supports the existing evidence that bone formation and bone resorption are coupled. Hence 
we would expect to see increased levels of markers of formation and resorption. Similar to what 
has been reported in other studies 32, study children with clinical signs of rickets had higher BAP 
concentrations which is expected for recovery.  
This RCT had several limitations. Detection of changes in bone turnover markers was not 
the primary outcome of this study. Consequently, we had limited power to detect changes in 
infant bone markers in response to supplementation. We also did not measure BMD and BMC 
that are better markers of bone health. CTX levels have been shown to be influenced by diurnal 
variations6. Due to logistical difficulties, our blood samples were not all drawn at the same time, 
and we did not adjust for time of collection during analysis. Thus our results should be interpreted 
with caution. Finally, due to ethical reasons, we were not able to collect fasting blood samples.  
 
Conclusion   
In conclusion, in this RCT vitamin D supplementation during lactation did not impact 
bone markers. Further studies should measure bone markers in non-pregnant and non- lactating 
women to characterize bone turnover in other life stages. Moreover, measurement of bone 
markers will enable the establishment of population-specific reference ranges.  
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Table 5.1. Baseline Characteristics of lactating women, Southern Ethiopia 2014  
 
  Control group  
(n= 59) 
Vitamin D group  
 (n= 56) 
P value  
Days postpartum 1  9 + 3.8  10.1 + 4.4  0.281 
BMI (kg/m2) 21.2 + 2.2 21.4 + 2.5 0.827 
Frame size2   0.636 
Small 10 (16.9) 9 (16.1)  
Medium 37 (62.7) 39 (69.9)  
Large  12 (20.3) 8 (14.3)  
Albumin (g/dL)  3.2 + 0.6 3.2 + 0.7 0.338 
Intact PTH (Pg/mL)3 54.7 (35.0, 86.3) 50.7 (35.0, 76.4) 0.381 
BAP (µg/L)  8.0(7.1, 10.7) 9.1 (7.1, 10.5) 0.370 
Osteocalcin (ng/mL)  10.5 (7.2,14.8) 9.8 (7.9, 15.9) 0.509 
CTX (ng/mL)  0.4 (0.3, 0.5) 0. (0.2, 0.6) 0.464 
Median interpregnancy Interval  36 (21.0, 45) 36 (24,60) 0.233 
Less than a year 7 (11.7) 5 (8.9)  
1 to 2 years 10 (16.7) 6 (10.7)  
2 to 5 years 15 (25.0) 19 (33.9)  
> 5 Years 4 (6.7) 4 (7.1)  
1 Mean + SD (all such values) 2 n(%) (all such values) 3 Median (25th percentile, 75th percentile) (all such values). Frame size= Height 
(cm)/ Wrist circumference (CM) ( Small frame > 11, Medium frame= 10.1-11 and Large frame < 10.1). PTH: Parathyroid hormone, 
BAP: Bone specific Alkaline phosphatase, CTX: Cross-linked telopeptide type 1 collagen.  
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Table 5.2. Bone turnover markers at baseline by vitamin D status in lactating women, Southern 
Ethiopia 2014 
 Vitamin D insufficient 
(25(OH)D < 50 nmol/L) 
(n= 69) 
Vitamin D sufficient 
(25(OH)D > 50 nmol/L) 
(n= 46) 
 
p value 
PTH (Pg/mL)1 62.1 (38.0, 85.9) 53.6 (32.3, 76.3) 0.101 
BAP (µg/L) 8.9 (7.2, 10.0) 9.7 (6.7, 12.3) 0.395 
Osteocalcin (OC) (ng/mL) 10.1 (6.7, 12.5) 14.6 (8.6, 19.7) 0.004 
CTX (ng/mL) 0.4 (0.3, 0.5) 0.4 (0.3, 0.5) 0.376 
                 1 Median (25th percentile, 75th percentile) (all such values) . PTH: Parathyroid hormone, BAP: Bone Specific Alkaline Phosphatase and  v                
                 CTX: C-terminal telopeptides of type 1 collagen 
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Table 5.3. Simple and multiple regression analysis for predictors of OC and CTX in lactating 
women at baseline, Southern Ethiopia 2014 
    95 % CI for β 
 β SE P Lower Upper 
OC Model1 
 
     
      
25(OH)D 0.004 0.002 0.011 0.001 0.008 
Maternal age -0.342 0.233 0.145 -0.804 0.12 
Days postpartum 0.027 0.006 < 0.001 0.016 0.038 
Adj. R2   22.1   
CTX Model2      
Days postpartum 0.016 0.004 < 0.001 0.008 0.025 
Adj. R2   11.5   
1 Predictors of OC in a Multiple regression analysis 2 Predictor of CTX in a simple regression 
analysis  
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Table 5.4. Maternal dietary calcium and phytate intake at 3 months postpartum, Southern 
Ethiopia 2015 
 Control  
group (n= 59) 
Vitamin D group  
 (n= 56) 
p value 
Dietary Calcium (mg/day)1 594 (385, 879) 663 (472, 894) 0.52 
Phytate: Calcium molar ratio1 0.20 (0.14, 0.30) 0.16 (0.10, 0.25) 0.077 
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Table 5.5 Correlation between bone turnover markers and 25(OH)D at baseline and end-line in lacataing women and infants, Southern 
Ethiopia 2014-2015  
 Baseline   End-line   
 25(OH)D OC BAP CTX   25(OH)D OC BAP CTX PTH 
25(OH)D 1     25(OH)D 1     
OC 0.238b 1    OC -0.035 1    
BAP  0.190a 0.481c 1   BAP  -0.205a 0.477c 1   
CTX 0.069 0.411c 0.223a 1  CTX 0.017 0.177 0.384a 1  
PTH -0.195a -0.021 -0.041 -0.040  PTH -0.195a 
0.249b 
0.365c 0.367c 1 
      Infant BAP -0.088 0.265b 0.219a 0.108 0.034 
    Values in table are Pearson correlation coefficients (r). OC: Osteocalcin, BAP: Bone Specific Alkaline Phosphatase, CTX: C-terminal telopeptides of type 1 
collagen,PTH: Parathyroid  hormone. a P < 0.05, b P < 0.01, c P < 0.001.  
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Table 5.6. Bone turnover markers at baseline and end-line by supplementation group among 
lactating women and infants, Southern Ethiopia, 2014 - 2015  
 Placebo Vitamin D P-value 
   Group  time Group x 
time  
BAP (µg/L)1      
Baseline  9.1 (7.1,10.7) 9.4 (7.1, 10.5) 0.471 0.018 0.216 
12 months 25.7 (16.4, 32.2) 23.6 (14.9, 29.0)    
Osteocalcin (ng/mL)      
Baseline  11.3 (7.2, 14.8) 12.6 (7.9, 15.9) 0.297 0.006 0.934 
12 months 20.4 (14.0, 27.2) 21.7 (14.8, 28.3)    
CTX (ng/mL)      
Baseline  0.42 (0.28, 0.52) 0.40 (0.24, 0.57) 0.999 0.127 0.593 
12 months 0.39(0.21, 0.59) 0.41 (0.21, 0.50)    
PTH (pg/mL)2      
Baseline  54.5 (34.7, 85.1) 50.7 (35.0, 76.4) 0.463 0.238 0.398 
12 months 57.9 (45.3, 84.4) 61.2 (42.9, 82.6)    
Infant BAP (ng/mL)3      
Baseline  -- --    
12 months 43.5 (26.8, 55.8) 49.5 (32.6, 67.1) 0.128 -- -- 
1 Median (25th percentile, 75th percentile) (all such values),2 Controlled for maternal age  
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CHAPTER VI 
 
 
EFFECTS OF MATERNAL VITAMIN D SUPPLEMENTATION DURING LACTATION ON 
INFANT GROWTH, GROSS MOTOR DEVELOPMENT AND MORBIDITY: RESULTS 
FROM A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL  
 
Abstract  
 
Background: Vitamin D is a potent modulator of the immune system. Furthermore, it plays an 
important role in bone mineral mineralization and skeletal growth. Studies that explore the role of 
vitamin D in the alleviation of infectious disease and promotion of growth are needed.  
Objective: To evaluate the effect of vitamin D supplementation provided to lactating women for 
12 months on infant growth, attainment of gross developmental milestones and incidence of 
common childhood illnesses.  
Methods: We conducted a double-blind, randomized controlled trial in Sidama Zone (7o N, 38o 
E), Southern Ethiopia. Lactating women (n=126) enrolled within two after delivery were 
randomized to receive weekly vitamin D3 (15,000 IU/week) or placebo for 12 months. Infant 
length, weight, and mid upper arm circumference (MUAC) were  measured at baseline, 3, 6, and 
12 months. Attainment of ten gross motor milestones and incidence of cough, diarrhea, vomiting 
and runny nose were assessed weekly. 
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Differences in anthropometric status  were tested using repeated measures ANOVA. Negative 
binomial regression analysis was performed to test differences in child illness incidences. 
Differences in the attainment of motor milestones between the two groups were tested using COX 
hazard ratios.  
Results:  Infant and maternal anthropometric indices were not significantly different between 
vitamin D and placebo groups at baseline. There was no significant difference in change in 
height-for-age Z scores (P=0.5), weight-for-age z scores (P=0.267) or weight-for-height z scores 
(P = 0.299) in the vitamin D group compared to placebo. There was also no significant difference 
in the attainment of gross motor milestones and incidence of common childhood illnesses.  
Conclusions: Vitamin D supplementation did not significantly affect growth, gross motor 
development or incidence of common childhood illnesses. Trial registered at clinicaltrials.gov 
(NCT02210884).  
 
Introduction  
Vitamin D has been shown to modulate innate and adaptive immune systems. It plays a 
role in the innate immune system through enhancing chemotaxis and the phagocytic capabilities 
of macrophages1. It also promotes the production of antibacterial peptides such as cathelicidins 
and defecins that destroy microbial agents such as Mycobacterium tuberculosis and other 
infectious agents2,3. Moreover, vitamin D down regulates inflammatory cytokines such as tumor 
necrosis factor (TNFα), interleukin 2 (IL- 2) and IL-12. Vitamin D also promotes T lymphocyte 
function and balance. This alteration in cytokine response and enhancement of innate immunity 
can explain associations between vitamin D and infectious disease4,5. Low plasma levels of 
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25(OH)D have been associated with increased infectious disease, including respiratory tract 
infections6,7.  
 Vitamin D regulates bone mineral metabolism and skeletal development. Adequate 
vitamin D is required for bone mineral accretion and skeletal development6. Vitamin D deficiency 
in children has been linked to linear growth retardation in the presence of rickets6,8. Children with 
vitamin D-dependent rickets present with secondary hyperparathyroidism and demineralization of 
the growing skeleton, as well as impairment of bone elongation9. Studies have shown treatment 
with vitamin D leads to resolution of hyperparathyroidism and catch up growth10. The 
relationship between child linear growth and vitamin D have not been explored widely. In a study 
in Indian, weekly vitamin D supplementation (1400 IU/week) of low birth weight infants reduced 
the risk of stunting11 In another study in Bangladesh maternal vitamin D supplementation (35, 
000 IU/week) starting the third trimester of pregnancy trough delivery resulted in higher length-
for-age z score at year one12. 
In sub-Saharan Africa, stunting occurs in more than a third of children and accounts for 
21% of disability- adjusted life years13. In Ethiopia despite a substantial decline in the past 
decade, 38% of children under five years of age are stunted14. Acute respiratory infection, fever, 
and diarrhea are important contributing causes of childhood morbidity and mortality. Infant 
mortality was 48 deaths per 1000 live births in the Demographic and Health Survey conducted in 
2015. Neonatal mortality rate is 29 deaths per 1000 live births14.  The role of vitamin D in 
immune function and bone health make it a viable option as a new intervention that can be used 
to improve maternal and infant health outcomes in low-income settings. To our knowledge no 
study has explored the role of vitamin D in relation to infant growth and morbidity in Ethiopia 
which has high infectious disease burden. Thus the aim of this study was to evaluate the effect of 
a vitamin D supplementation on infant growth, attainment of gross developmental milestones and 
incidence of common childhood illnesses.  
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Methods   
 
Trial design  
The study was a parallel group, double-blind, randomized, controlled vitamin D 
supplementation trial conducted from October 2014 to January 2016. Lactating women enrolled 
in the trial within two weeks after delivery were randomized to one of the study groups and 
received 15,000 IU vitamin D3 or placebo capsules weekly for 12 months. Ethical clearance for 
the study was obtained from the Oklahoma State University Institutional Review Board, the 
Hawassa University Institutional Review Board and the Ethiopian National Health Research 
Ethics Review Committee and the Food, Medicine and Health Care Administration and Control 
Authority of Ethiopia (FMHACA). The trial was registered at clinicaltrials.gov (Registration 
number: NCT02210884). 
Participants 
 The study was conducted in four subsistance farming communities (Alamura, Finchawa, 
Chefe Koti Jebesa, and Tullo) in Southern Ethiopia (7oN, 38oE). Lactating women and infant 
dyads were enrolled in the study if: they were apparently healthy, delivered within two weeks, 
were currently breastfeeding, and planned to continue breastfeeding for 12 months.  
Outcome assessments  
Anthropometric measurements  
  Maternal height, weight, mid-upper arm circumference (MUAC), and wrist 
circumference were measured at baseline, 3 and 6 and 12 months. Infant weight and MUAC were 
also measured at these time points. Infant recumbent length was measured at 3, 6 and 12 months. 
Measurements were taken using standardized techniques and calibrated equipment. Height and 
length were measured to the nearest 0.1 cm using the Shorr measuring board (Shorr Productions, 
Olney, MD, USA). Weight was measured to the nearest 0.1kg using a digital scale (SECA 
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Uniscale, UNICEF, Copenhagen). At baseline, infant weight was measured to the nearest 0.01 kg 
using a portable baby scale (SECA354, UNICEF, Copenhagen) and was measured with the 
SECA Uniscale weighing scale on subsequent visits. A non- stretchable Teflon measuring tape 
was used to measure MUAC and wrist circumference. Infant anthropometric indices; length-for-
age (LAZ), weight-for- age (WAZ), weight-for-height (WHZ), and BMI-for-age (BMIZ) were 
calculated from the measurements using the WHO Anthro software (Version 3.2.2.). Stunting 
(short for age) was defied as LAZ < -2. Underweight (thin for age) was defined as WAZ < -2. 
Wasting was defined as WLZ < -2. 
Infant Morbidity  
Trained community research workers (CRW) assessed the incidence of common 
childhood illnesses weekly during home visits. Illnesses were defined based on the WHO 
Integrated Management of Childhood Illness (IMNCI) guidelines15. CRWs asked the mother the 
number of times the infant had vomited, coughed, and had diarrhea in the past seven days. 
Vomiting was defined as the forceful evacuation of stomach contents. Reflux, which is common 
in breastfeeding infants was not counted as vomiting. Diarrhea was defined as three or more loose 
stools in a day. The CRWs also observed if the child had a runny nose at the time of the visit. 
Sick children were referred to the local health post or hospital for treatment. Longitudinal 
prevalence was calculated using the number of days an infant had the outcome (illness) as a 
numerator and the total number of days the outcome was assessed (visit) as a denominator.   
Infant Gross Motor Development  
Attainment of gross motor milestones by infants was assessed by CRWs weekly (See 
Appendix 2 for testing procedures and criteria). Four milestones (1. Raising head when on front, 
2. Bearing weight on legs, 3. Sitting supported by arm, 4. Turning and rolling over ) were used 
from the Denver Developmental Scale screening test II 16 All the gross motor milestones used in 
the World Health Organization (WHO) multicenter growth reference study17 were also used 
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together with the Denver II milestones. The WHO gross motor milestones were sitting without 
support, hands and knees crawling, standing with support, standing unsupported, walking 
supported and walking unsupported.  
 
Statistical methods  
Data were analyzed using SAS (Version 9.4, SAS Institute Inc., 2013) and IBM SPSS 
(version 23, 2016, IBM Corp.) Normality was tested using the one-sample Kolmogorov-Smirnov 
test. Variables that were skewed were transformed using log transformation. Differences in 
anthropometric indices were tested using repeated measures ANOVA. An independent-sample t- 
test was used to test cross-sectional mean differences. Chi-square test was used to test proportion 
differences. Negative binomial regression analysis was performed to test differences in child 
illness incidences. Differences in the attainment of motor milestones between the two groups 
were tested using COX hazard ratios (Survival analysis). Statistical significance was set at P< 
0.05. 
 
Results  
A total of 152 mother-infant pairs were assessed for eligibility. In total, 126 mothers were 
randomized into intervention (n=63) and control (n=63) groups (Figure 3.1). Baseline 
characteristics of the study groups were similar (Table 6.1). Compliance and loss to follow-up 
were similar between the placebo and Vitamin D groups.  
We found no statistical difference in attainment of all 10 motor milestones between the 
placebo and intervention group (Table 6.2). In addition, no significant differences were seen in 
the first incidence or longitudinal prevalence of common childhood illnesses (Table 6.3). 
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There were no statistically significant differences in the change in LAZ, WAZ, WHZ, 
MUACZ and BMI-for-age over time between study groups (Table 6.4). At 3, 6, and 12 months 
fewer children tended to be stunted and underweight in the vitamin D group compared to placebo 
group (Table 6.5). Wasting tended to be higer in the treatment group at 3 months.  
 
Discussion 
This study investigated the effects of vitamin D supplementation to lactating mothers on 
growth and morbidity of their infants in a setting with high prevalence of growth faltering and 
heavy burden of infectious. The intervention resulted in significant improvements in maternal 
25(OH)D concentrations. However, we found no significant effect of the intervention on infant 
growth, gross motor development, or morbidity.   
Vitamin D is important for fetal growth and bone development2. Several studies have 
shown that improved vitamin D status during pregnancy can result in improved birth outcomes18. 
In this study maternal 25(OH)D concentrations at baseline were not related to infant weight. This 
finding is in agreement with a study conducted in a similar setting among Gambian 19 women 
with comparable maternal 25(OH)D with women in our study. Maternal 25(OH)D concentrations 
were measured at 20 weeks and 36 weeks during pregnancy and all women were vitamin D 
sufficient (> 50 nmol/L). Vitamin D status was not related to birth weight and growth, and did not 
influence infant weight, length, head circumference and bone mineral accretion (BMC and BMD) 
at any time during 52 weeks of postpartum follow-up. Furthermore, in a Dutch multi-ethnic 
cohort, vitamin D deficiency ( < 30 nmol/L) and not insufficiency and adequacy were 
significantly associated with lower birth weight and a higher risk of SGA20.  
The lack of an overall intervention effect on infant growth and motor development is 
consistent with previous studies. In a cross-sectional analysis of the association between vitamin 
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D status and gross motor performance in 912 Indian children aged 5 years, vitamin D status was 
not associated with motor performance21. In contrast, among low birth weight infants 
supplemented with vitamin D (1400 IU/week) from 1 week to 6 months of age the intervention 
resulted in increased length and weight at 6 months11. However, when these children were 
followed at age 3 to 6 years, children in the vitamin D group had lower BMI_for_age z scores, 
thigh circumference and arm muscle area and borderline lower mid-upper arm circumference 
showing that effects seen earlier were not preserved in the long-term 22.  
However, several studies have shown a negative relationship between vitamin D 
deficiency and infant growth. A large US multi-center cohort study (n= 2473) tested the 
association between maternal 25(OH)D at 26 weeks of gestation and infant length-for-age z score 
(LAZ) at birth, 4 , 8 and 12 months. In this study, infants whose mothers were not deficient had 
significantly higher LAZ across the first year of life compared to infants whose mothers were 
vitamin D deficient (< 30 nmol/L)23. Furthermore, in Mongolian school children (n=113) with 
low baseline mean 25(OH)D (17 nmol/L), 6 month supplementation with 800 IU/day of vitamin 
D resulted in a statistically significant greater increase in height compared to children who 
received placebo24. The lack of effect of the intervention on growth in this study might be due to 
the fact that baseline 25(OH)D status (an indicator of maternal status during pregnancy) was 
much higher (45 nmol/L and 46 nmol/L in the placebo and vitamin D groups) compared to these 
studies that reported positive relationships with vitamin D status and growth.  
We hypothesized that improved vitamin D status would modulate infant immune 
response to infectious challenges and downregulate inflammation, which would subsequently 
result in reduced morbidity. However, we were unable to detect an effect on morbidity. In a study 
that supplemented low birth weight infants with vitamin D (1400 IU/week) or placebo for 6 
months 25, the authors found no significant differences in C-reactive protein (CRP), tumor 
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necrosis factor-a (TNFa), interferon-g (INFg), interleukin (IL)-10 and IL-13. These findings 
suggest that vitamin D supplementation might not have influenced inflammation in our study. 
Continuing with what has been reported for growth, beneficial effects of vitamin D in relation to 
morbidity have been reported in vitamin D deficient populations. In Mongolian school age 
children who received vitamin D fortified milk (300 IU) or unfortified milk for 7 weeks, 
compared with control, children receiving vitamin D fortified milk had lower incidence of acute 
respiratory infections26. Baseline 25(OH)D ranged between 12.5 and 25 nmol/L in the children. In 
a cross-sectional analysis newborns with acute lower respiratory tract infections had lower mean 
25(OH)D concentrations (23 nmol/L) compared to healthy controls and more had values less than 
25 nmol/L27.  
This study provides additional data on the lack of relationship between vitamin D status 
and infant growth, gross motor development and morbidity. The main limitation of this study is 
its small sample size. Growth and morbidity were not primary outcomes hence we had low power 
to detect the effect of vitamin D on the infant functional outcomes discussed in this paper. 
Furthermore, our morbidity assessment relied on recalled infant events. For ethical purposes, we 
were required to cover health costs of the study participants. This combined with close follow-up 
of subjects may have led to reduced morbidity incidences compared to the general population. 
We also did not measure markers of inflammation in the study participants.  
Conclusion  
In conclusion, in this study, vitamin D supplementation of lactating mother starting from 
2 weeks post-partum to 12 months had no effects on infant growth and gross motor development 
in a population where growth is influenced by multiple factors. The intervention did not also 
improve incidence of common childhood illnesses.   
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Table 6.1. Infant characteristics at baseline, Southern Ethiopia 2014 
 Control  
(n=59) 
Vitamin D group  
(n=56) 
 
P-value 
Infant Age (age)1 9.3 (3.8) 10.1 (4.4) 0.281 
Infant Weight (kg) 3.3 0(0.5) 3.4 (0.5) 0.889 
Infant MUAC (cm) 10.5 (0.8) 10.6 (0.8) 0.413 
Weight-for-age Z score -0.4 (1.0) -0.4 (0.9) 0.834 
Maternal weight (kg) 54.2 (7.4) 53.8 (7.3) 0.804 
Maternal Height (m) 1.6 (0.06) 1.6 (0.06) 0.373 
Maternal MUAC (cm) 25.3 (2.3) 25.2 (2.50 0.825 
BMI (kg/m2) 21.2 (2.2) 21.3 (2.5) 0.697 
1Mean(SD). MUAC: Mid upper arm circumference. BMI: Body Mass Index 
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Table 6.2. Infant mean motor milestones attainment by supplementation group, Southern Ethiopia 
2015 
Gross motor milestones Control Treatment Exp(B) (95% CI)1 
Raise head when lying on front1 82.0 (19.4) 85.2 (22.8) 0.82 (0.6,1.2) 
Bears weight on leg 98.1(23.8) 103.6 (22.9) 0.83 (0.6, 1.2) 
Chest up arm support 135.1 (31.6) 145.1 (40.0) 0.76 (0.5, 1.1) 
Turning and rolling over  144.4 (29.7) 144.7 (29.6) 0.98 (0.7, 1.4) 
Sitting without support 154.4(24.7) 151.9 (19.5) 1.15 (0.8, 1.7) 
Hands and knees crawling 248.3 (35.5) 244.7 (26.6) 1.17 (0.8, 1.7) 
Standing with assistance  266.4 (35.6) 261.96 (31.97) 1.18 (0.8, 1.7) 
Walking with assistance 30.2.1 (30.36) 303.8 (31.1) 0.90 (0.6, 1.3) 
Standing alone 325.3 (37.1) 331.3 (41.4) 0.83 (0.5, 1.3) 
Walking alone 346.8 (43.4) 357.7 (45.5) 0.96 (0.6, 1.5) 
2 Mean(SD) values in table show mean days of attainment, 1 Cox Hazard ratio using the control group as 
reference (1) 
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Table 6.3. Infant morbidity outcomes by supplementation group, Southern Ethiopia 2015  
 
Morbidity outcomes  Placebo Vitamin D P-value 
Incidence of childhood illnesses1 
Cough  37 (61.6) 35 (62.50) 0.981 
Runny nose  50 (83.3) 47 (83.9) 0.904 
Vomiting 34 (56.67) 26 (46.43) 0.230 
Diarrhea 41 (68.3) 36 (64.3) 0.553 
 
Longitudinal prevalence of childhood illnesses2 
Cough  0.03 0.03 0.911 
Runny nose  11.86 11.84 0.605 
Vomiting 0.02 0.02 0.53 
Diarrhea 0.03 0.02 0.244 
1 n(%) all such calues. Incidence represents first incence of event. 2 Mean(SD) Longitudinal prevalence = 
number of days the infant had illness/ total number of days visit 
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Table 6.4. Infant mean anthropometric Z scores by supplementation group, Southern Ethiopia 
2015   
Anthropometric Indices  Placebo Vitamin D P-value 
Height-for-age1   0.5 
   3 months -0.5 (1.2) -0.1 (1.2)  
   6 months -0.9 (1.3) -0.7 (0.8)  
   12 months  -1.2 (1.2) -1.3 (0.9)  
Weight-for-age   0.267 
   Baseline  -0.4 (0.9) -0.4 (0.9)  
   3 months -0.2 (1.2) 0.1 (1.0)  
   6 months -0.3 (1.3) -0.01 (1.0)  
   12 months  -0.5 (1.1) -0.4 (0.9)  
Weigh-for-Height    0.299 
   3 months 0.3 (1.1) 0.3 (1.5)  
   6 months 0.4 (1.1) 0.6 (1.0)  
   12 months  0.1 (0.9) 0.3 (1.0)  
BMI-for-Age   0.179 
   3 months 0.1 (1.1) 0.2 (1.4)  
   6 months 0.2 (1.1) 0.6 (1.0)  
   12 months  0.2 (0.9) 0.5 (1.0)  
MUAC-for-age   0.320 
   3 months -0.01 (1.1) 0.1 (0.9)  
   6 months -0.1 (1.7) 0.1 (0.9)  
   12 months  -0.2 (1.1) 0.04 (0.9)  
1 Mean (SD) all such values 
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Table 6.5. Incidence of growth faltering by supplementation group, Southern Ethiopia 2015   
Anthropometric Indices  Placebo Vitamin D P-value 
Stunting     
      3 months 6 (5.2) 1 (0.9) 0.065  
      6 months 13 (11.3) 7 (6.1) 0.178a 
     12 months  15 (13.2) 10 (8.7) 0.325a 
Underweight      
      3 months 3 (2.6) 2 (1.7) 0.525 
      6 months 7 (6.1) 2 (1.7) 0.094 
     12 months  6 (5.2) 2 (1.7) 0.153 
Wasting     
      3 months 1 (0.9) 5 (4.3) 0.092 
      6 months 2 (1.7) 0 0.216 
     12 months  1 (0.9) 0 0.513 
 a Chi-square test. All other P-values are for Fisher’s exact test.  
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CHAPTER VII 
 
 
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS  
Summary of finding  
The purpose of this study was to determine the effects of a weekly vitamin D supplement 
(15,000IU) vs. placebo administered to lactating women (for 12 months starting from 2 weeks 
after birth) on maternal and infant markers of vitamin D status. Secondary outcome measures 
considered include maternal markers of bone turnover, infant growth, infant gross motor 
developmental milestones and incidence of common childhood illnesses.  
Null hypothesis for primary objectives  
.HO1: There is no significant differences in maternal 25(OH)D concentration between the 
treatment and control groups.  
- HO1 was rejected since there was a significant difference in maternal 25(OH)D 
concentrations between the placebo and control group  
HO2: There is no significant differences in infant 25(OH)D concentration between the treatment 
and control groups.
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- We failed to reject this hypothesis since there was no significant differences in infant 
25(OH)D concentrations between groups.  
HO3: Skin reflectance, UVB exposure and dress habits will not significantly predict 25(OH)D 
concentrations. 
- We failed to reject this hypothesis since skin reflectance, UVB exposure and percent 
body surface area exposed were not significantly associated. 
Null Hypothesis for secondary objectives  
HO1: There is no significant difference in parathyroid hormone (PTH) concentrations between the 
treatment and control groups.  
- We failed to reject this hypothesis as PTH was not significantly different between the v 
vitamin D and placebo group. 
HO2: There is no significant difference in maternal and infant bone specific alkaline phosphatase 
(BAP) concentrations between the treatment and control groups.  
- We failed to reject this hypothesis as BAP was not significantly different between the 
vitamin D and placebo group. 
HO3: There is no significant difference in osteocalcin (OC) concentrations between the treatment 
and control groups.  
- We failed to reject this hypothesis as OC was not significantly different between the 
vitamin D and placebo group. 
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HO4: There is no significant difference in C-terminal telopeptides of type 1 collagen (CTX ) 
concentrations between the treatment and control groups.  
-  We failed to reject this hypothesis as CTX was not significantly different between the 
vitamin D and placebo group. 
HO6: There is no significant difference in the date of attainment of gross motor milestones 
between infants of mothers in the treatment and control group. 
- We failed to reject this hypothesis as date of attainment was not significantly different 
between the vitamin D and placebo group. 
HO7: There is no significant difference in the infant growth between infants by treatment group. 
- We failed to reject this hypothesis as infant growth was not significantly different 
between the vitamin D and placebo group. 
HO7: There is no significant difference in the incidence of common childhood illnesses between 
infants of mothers in the treatment and control group. 
- We failed to reject this hypothesis as incidence of illness was not significantly different 
between the vitamin D and placebo group. 
 
Conclusions and recomedations for future research  
 Weekly Vitamin D3 (15,000 IU/week) supplementation of lactating women 
starting 2 weeks post-partum and extending to 12 months significantly improved maternal 
25(OH)D. However, the intervention did not result in a significant difference in infant 25(OH)D, 
maternal and infant markers of bone turnover, infant growth, gross motor development or infant 
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morbidity. Further research is needed to confirm if the results of this study can be replicated in 
similar settings. Future studies should also quantify vitamin D synthesis through UVB exposure 
for 117 infants. Large randomized controlled trials that powered to detect functional outcomes are 
needed to establish the benefit of vitamin D supplementation on functional outcomes related with 
bone health, infant growth and morbidity 
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APPENDICES 
 
Appendix 1: Percent body surface area exposed sunlight calculation  
  
   Head Top Bottom 
 Rule of 
nines108 
Adapted 
value 
No 
Head scarf 
No 
neck scarf 
No 
sleeve 
Short 
sleeve 
Long 
sleeve 
Long 
bottom 
Short 
bottom 
Anterior head 3.5 3.5  
 
     7     
   (0.07) 
 
 
2 
(0.02) 
     
Posterior head 3.5 3.5      
Anterior neck 1 0.75      
Posterior neck 1 1.25      
Anterior upper arm (Both) 4 4    
 
 
20  
(0.20) 
 
 
 
12  
(0.12) 
 
 
 
 
 
6  
(0.06) 
  
Posterior upper arm (Both) 4 4     
Anterior lower arm (Both) 2.5 3     
Posterior lower arm (Both) 2.5 3     
Anterior hand (Both) 2.5 3     
Posterior hand (Both) 2.5 3     
Anterior upper leg ( Both) 9.5 9.5        
Posterior upper leg (Both) 9.5 9.5        
Anterior lower leg (Both) 7 5       
2  
(0.02) 
 
12  
(0.12) 
Posterior lower leg (Both) 7 5      
Foot 3 2      
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Appendix 2: Gross motor milestone testing procedure and performance criteria  
No. Gross motor milestone  Testing procedure Performance criteria 
1.  Raise head when lying on front 
 
Place the child on his/her 
stomach on a flat surface. 
Child lifts head so that face makes an 
approximate 45 degree angle with the 
surface for 10 seconds. 
2. Bears weight on legs Hold the child in standing 
position, his/her legs and feet 
on a flat surface. Then slowly 
loosen your hand support. 
 
Child is able to support weight on legs 
and feet when support is lessened for 
5 seconds. 
3. Chest up arm support (sitting 
supported by arm) 
 
 
 
Place the child on his/her 
stomach on a flat surface 
 
Child lifts head and chest off the 
surface using the support of 
outstretched arms. 
 
Child is looking straight ahead or up. 
4. Turning and rolling over 
 
Place the child on his/her 
stomach/back. 
The child rolls from back to stomach 
or from stomach to back. 
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5. Sitting without support
 
Facing the child and smiling, 
places the child in a sitting 
position. 
 
Than give the child an object 
to handle with both hands. 
Child sits up straight with the head 
erect for at least 10 seconds. 
 
 
 Child does not use arms or hands to 
balance body or support position. 
6.  Hands-and-knees crawling 
 
Places the child in the prone 
position with the abdomen 
above the supporting surface. 
CRW places herself in front of 
the child.  
 
If the child does not crawl 
spontaneously, show the child 
an object that attracts the 
child’s visual attention. 
 
Child alternately moves forward or 
backward on hands and knees. 
 
The stomach does not touch the 
supporting surface.  
 
There are continuous and consecutive 
movements, at least three in a row 
7.  
 
 
Standing with assistance 
 
Place the child in a standing 
position by holding onto a 
stable object (e.g., furniture)  
  
 
Child stands in upright position on 
both feet, holding onto a stable object 
with both hands without leaning on it. 
 
The body does not touch the stable 
object, and the legs support most of 
the body weight.  
 
Child stands with assistance for at 
least 10 seconds 
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8.  Walking with assistance 
 
Place the child in a standing 
position by holding onto a 
stable object (e.g., furniture).  
 
If the child does not move 
spontaneously, show the child 
an object that attracts the 
child’s visual attention.  
Child is in upright position with the 
back straight. Child makes sideways 
or forward steps by holding onto a 
stable object with one or both hands.  
 
One leg moves forward while the 
other supports part of the body 
weight.  
 
Child takes at least five steps. 
 
9.  Standing alone 
 
 
Place the child with both feet 
flat on the floor and supports 
the child to an erect position.  
 
Then withdraw the support 
gradually and temporarily. 
Child stands in upright position on 
both feet (not on the toes) with the 
back straight. 
 
The legs support 100% of the child’s 
weight.  
 
There is no contact with a person or 
object. Child stands alone for at least 
10 seconds. 
10 
 
 
 
Walking alone 
 
Place the child in an erect 
position out of the reach of any 
supporting object.  
 
Child takes at least five steps 
independently in upright position with 
the back straight.  
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Stand one or two steps in front 
of the child and call the child 
to move towards you. 
One leg moves forward while the 
other supports most of the body 
weight.  
 
There is no contact with a person or 
object. 
- Date of attainment will be recorded in consultation with the mother.  
-The CRW must see when the child performs the milestones.  
- If the child does not perform one milestone for 3 consecutive visits (recorded 2) inform                              
the researcher. 
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Appendix 3: Infant illness referral and reporting chart 
 
  
Signs and Symptoms Where to refer  When to notifying 
investigators  
Urgent referral signs and symptoms    
Danger signs   
 
If the child has one of 
these danger signs 
Urgently refer to 
Bushulo, Health 
Center, Referral or 
Adare Hospital  
 
 
 
 
Immediately  
1. Is not able to eat or breastfeed  
2. Vomits everything 
3. Has had convulsions or has current convulsions 
4. Is Lethargic or unconscious  
Other signs  
5. Cough with: fast breathing (>50 breaths per 
min) 
6. Long lasting fever ( 7 days)  
7. Diarrhea with: Sleepy or unconscious, Sunken 
Eyes, and Blood in stool  
8. Ear problem with swelling around the ears 
 Referral : Other signs and symptoms   
1. Cough  Refer to Health Center 
or Hospital  
 
Weekly  
(through weekly 
report form or 
thorough phone 
calls) 
2. Diarrhea (Irritable or restless, Drinks eagerly) 
3. Fever 
4. Ear infection : Liquid in ear for 2 weeks  
5. Eye infection  
6. Generalized rash 
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Appendix 4: Questinnaires  
 
Effects of maternal vitamin D supplementation on markers of  vitamin D 
Status and related infant and maternal health outcomes in Southern 
Ethiopia 
 
 Baseline  maternal questionnaire  
 
 
 
        
 
        Part I. Demographic and socioeconomic characteristics 
 
No. 
Questions  Responses  
1. How old are you?   
( Interviewer: How certain was the mother 
about age 1. Certain  2. Fairly certain 3. 
Uncertain)  
      
________________ Years 
   
2. What is your current marital status?  1. Married  
2. Single 
3. Divorced 
4. Widowed   
   Others (specify)  
____________________                    
3. What is your religion?  
 
1  Orthodox Christian  
2.  Muslim   
3.  Protestant  
4.  Catholic   
   Others (specify) 
___________________ 
4. How many people reside in your home?     ______________ Household members 
5. What is the highest grade/number of years of 
school you completed?   
     ____________ Years  
        
       99. Non-formal education  
6. What is the highest grade/number of years of 
school your husband/partner has completed?   
     ____________ Years  
        
       99. Non-formal education  
7.  What is your occupation? 1. Housewife 
2. Daily-laborer 
3. Employed government 
4. Employed non-government 
5. Petty trade  
Others (specify) 
____________________ 
8. What is the occupation of the father?  1. Farmer  
2. Employed government 
3. Employed non-government  
4. Daily-laborer 
Interviewer _________________ Date of data Collection ___/____/___ 
Child birth date___/____/___        Child sex____________ Village _________ 
 
Maternal code: 
____________ 
 135 
5. Self-employed non farming  
Others (specify)____________________ 
 
 
 
 
  
9. Do you have any of the following things in 
your house that are functioning?  
 
1. Electricity  
2. Radio/ tape player  
3. Television  
4. Bicycle  
5. Motor bike    
6. Car       
7.   Mobile telephone  
8.   Non-mobile telephone 
9.   A savings account   
10. How many rooms do you have in your house?  _______________________ Rooms  
 
11. Does your house have a separate kitchen? 0.  No   
1. Yes                                
12.  What material is the roof of your house made of?  
 
 
  
1. Thatched roof  
2. Plastic sheets 
3. Corrugated iron  
4. Cement/ concrete  
Others (specify)___________________ 
13.   What material is your floor made of?  
  
1. Natural floor (earth)   
2. Cow dung 
3. Wood 
4. Cement          
        Others 
(specify)______________________ 
14. What material is the inside wall  of your house? 1. Wood with mud  
2. Stone with mud  
3. Cement/ Cement blocks  
4. Brick  
Others 
(specify)____________________ 
15. What is the main source of drinking water for 
members of your household?  
 
1. River/ Lake              
2. Spring   
3. Well 
4. Public/ shared  tap  
5. Private tap                 
        Others (specify) 
____________________   
16. How long does it take you to go to your water 
source, get water and come back home?  
  
           _____________________Minutes  
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17. What kind of toilet facility does your household 
use?    
 
(If the respondent does not understand ask to 
observe the toilet and circle the appropriate 
answer.)  
 
 
1. No facility/Bush/field  
2. Pit latrine without slab   
3. Pit latrine with slab cover  
4. Ventilated improved pit latrine 
5. Flush toilet  
       Others (specify) 
____________________ 
18. Is the toilet facility shared with other households?  0.  No   
1. Yes                                
19. Does your household own agricultural land?  0.  No   
1. Yes                                
20. How many units (local) of land does your 
household own?  
 ______________ hectare 
 or_____________ timad  
21. Which crops do you grow? 
  
 (Read the list) 
                             Yes            No 
1.Coffee                1                 0 
2.Chat                    1                 0 
3.Maize                 1                 0 
4.Enset                  1                 0 
5.Barley                1                 0  
6.Sugar cane         1                 0 
   Others (specify)___________________ 
22. Does the household own any of the listed animals?  
(Read the list) 
 
Cows 
Oxen  
Horse/ Donkey  
Sheep 
Goat  
Chicken  
 
  
 
 
 
 
No Yes Number  
0 1 _______ 
0 1 _______ 
0 1 _______ 
0 1 _______ 
0 1 _______ 
0 1 _______ 
 
Part II Maternal care  and  dietary practice 
23. How many children did you give birth to?   _______________ Number  
24. How many children are living ?  ____________________ 
25. Did you receive antenatal care at a health facility  
during you last pregnancy?  
0.  No  (Skip to 29) 
1. Yes                              
26. If yes whom do you usually see? 
 
( More than one answer possible) 
1. Doctor 
2. Nurse/midwife 
3. Health extension worker  
Others (specify)___________________ 
27. Where did you receive antenatal care?  1. Government hospital 
2. Public hospital  
3. Public health center  
4. Health post  
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Others (specify)___________________ 
28. How many months pregnant were you when you 
first received antenatal care?  
______________________ Months  
29. How many times did you receive antenatal care 
during your last pregnancy?  
________________________ 
30. Where did you give birth to your last baby 
(NAME)? 
1. Home 
2. Public hospital or health center  
3. Private hospital or health center  
Others 
(specify)_____________________ 
31.  If NAME was born at home, why did you not 
deliver in a health facility?  
 
1. Cost  
2. Facility not open 
3. Facility too far 
4. Family did not allow 
5. Afraid to go to a health facility    
      Others 
(specify)_____________________ 
32. Were any of your children delivered by caesarean? 
 (Did they cut your belly to take the baby out?) 
0.  No   (Skip to 33) 
1. Yes    
33. Was your last baby (NAME) delivered by 
caesarean  
0.  No   
1. Yes                                
34. Did you take any supplements (Iron/folic acid 
iodine, or other) when you were pregnant with 
your last child?  
 No Yes 
Iron/folic 
acid 
0 1 
Iodine  0 1 
Other 
(specify) 
_______________________ 
 
35. Did you take cod liver oil during pregnancy?  0.  No   
1. Yes                                
36. Did you take cod liver oil since giving birth?  0.  No   
1. Yes                                
 
Part IV  Household hunger index  
 
37. In the past month was there ever no food to 
eat in your house because of lack of resources 
to get food? 
0.  No   ( Skip to 38 ) 
1. Yes                                
38. How often did this happen in the past month? 1. Rarely (1-2 times) 
2. Sometimes (3-10 times) 
3. Often ( more than 10 times)  
39. In the past month did you or any household 
member go to sleep at night hungry because 
there was not enough food? 
0.  No   ( Skip to 40) 
1. Yes                                
40. How often did this happen in the past month? 1. Rarely (1-2 times) 
2. Sometimes (3-10 times) 
3. Often ( more than 10 times)  
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41. In the past month did you or any household 
member go a whole day and night without 
eating anything at all because there was not 
enough food? 
0.  No   ( Skip to 42 ) 
1. Yes                                
42. How often did this happen in the past month? 1. Rarely (1-2 times) 
2. Sometimes (3-10 times) 
3. Often ( more than 10 times)  
43. How many times did you eat yesterday? 
( Coffee not counted) 
1. Once 
2. Twice 
3. Three times 
4. More than three times  
 
Part IV  Child feeding practices 
 
44. Are you breastfeeding your last child (NAME) ?  0.  No  ( Skip to 45) 
1. Yes                                
45. How long after birth did you start breastfeeding 
NAME ?  
0. Immediately  
_______________Hours 
 _______________ Days 
46. After delivery was NAME given anything to drink 
other than breast milk?  
0.  No  (Skip to 47) 
1. Yes                                
47. What was NMAE given to drink?  1. Milk other than breast milk  
2. Plain water 
3. Sugar with water 
4. Fenugreek 
5. Cod liver oil  
Other 
(specify)_________________________ 
48. Was the child given any supplements after birth?  
 
  
 No Yes 
Vitamin 
A 
0 1 
Iodine  0 1 
Other  _______________________ 
 
49. For how long do you intend to exclusively 
breastfeed NAME? 
_________________________Months  
 
50. For how long do you intend to breastfeed NAME?  _________________________Months  
 
51. Do you own a baby bottle? 0.  No   
1. Yes                                
52. Do you bottle feed NAME? 0.  No  (Give positive reinforcement)  
1. Yes                                
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Part IV Sun exposure behavior  
 
53. Did you expose your previous child to the sun?  0.  No   
1. Yes             
2. First baby                     
54. If yes how long after birth did you start exposing 
your baby to sunlight?   
_________days  
_________ Weeks  
55. Do  you plan on exposing your last baby NAME to 
the sun? 
_________days  
_________ Weeks  
56. Do you usually stay outside in the sun without an 
umbrella? 
0.  No   
1. Yes                               
57. If yes how often do you stay outside?  0. Once every two weeks  
1. Once per week 
2. Twice per week  
3. Every other day 
4. Daily 
Other 
(specify)_________________________ 
58. On a typical day for how long do you stay outside?  _______________Minutes 
_______________ Hours  
59. How would you characterize your typical dress 
style when you stay outside? 
 
( Interviewer: Show the respondent the clothing 
picture chart and record the appropriate letter) 
 
Head wear____________________ 
            Blouse_______________________ 
            Skirt _________________________ 
59. How would you characterize your typical dress 
style when you are at home?  
 
( Interviewer: use picture chart) 
Head wear____________________ 
            Blouse_______________________ 
   Skirt _________________________ 
60. How often do you wear sleeveless clothes? 0. Never 
1. Once every two weeks  
2. Once per week 
3. Twice per week  
4. Every other day 
5. Daily 
Other 
(specify)_________________________ 
61. How often do you wear short sleeve clothes? 0. Never 
1. Once every two weeks  
2. Once per week 
3. Twice per week  
4. Every other day 
5. Daily 
Other 
(specify)_________________________ 
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62. How often do you wear long sleeve clothes?  0. Never  
1. Once every two weeks  
2. Once per week 
3. Twice per week  
4. Every other day 
5. Daily 
Other 
(specify)_________________________ 
63. Do you avoid staying out in the sun? 0.  No   
1. Yes                                
64. If yes why do you avoid sunlight? ____________________________________ 
____________________________________ 
 
65. Please describe all the outdoor activities you performed yesterday, including walking outside, from 
early in the morning until sundown?  
 
(Interviewer: Start with the first outdoor activity and list all the activities performed in the day. 
Use the clothing style picture chart to record the type of cloth worn during each activity. Probe for 
activities. ) 
 
Time of 
day 
Outdoor activity Time spent 
on activity 
Clothing worn 
during activity 
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
 
Thank you for your time!!! 
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Effects of maternal vitamin D supplementation on markers of  vitamin D 
Status and related infant and maternal health outcomes in Southern 
Ethiopia 
 
 Follow up maternal questionnaire  
 
 
 
        
  
Part I  Dietary practices and household hunger index  
1.  Did you take any supplements in the 
past three months?  
 No Yes 
Iron 0 1 
Cod liver oil 0 1 
Other (specify) _______________________ 
 
2.  Did your last child (NAME) recently 
take any supplements?  
 
 No Yes 
Vitamin A 0 1 
Cod liver oil 0 1 
Other (specify) _______________________ 
 
3. Are you breastfeeding your last child 
NAME?  
0.  No  ( Skip to 7 ) 
1. Yes                                
4. After delivery was NAME given 
anything to drink other than breast 
milk?  
( Asked only at 3 months ) 
0.  No  (Skip to 6) 
1. Yes                                
5. If yes what was NAME given to 
drink? 
_________________________________ 
 
6.  For how long do you intend to 
exclusively breastfeed NAME? 
 
( Asked only at 3 months ) 
_________________________Months  
 
7.  Do you bottle feed NAME? 0.  No  (Give positive reinforcement)  
1. Yes                                
8. Have you started giving NAME any 
semi-solid or solid foods?  
0.  No   (Skip to 11) 
1. Yes                                
9. If yes how many times was NAME 
given semi-solid or solid foods 
yesterday? 
_________________________ 
10 Did NAME eat any of the foods/food 
groups listed yesterday?  
 No Yes 
Grains, roots and tubers 0 1 
Legumes and nuts 0 1 
Dairy  products 0 1 
Meat, fish, poultry 0 1 
Eggs 0 1 
Vitamin A rich fruits and vegetables  0 1 
Cod liver oil 0 1 
 
Name of mother_____________________           Name of child________________________  
 
Maternal code: 
____________ 
Interviewer _________________ Date of data Collection ___/____/___ Child sex________   
Village _________  
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11. Have  you ever seen a child with 
rickets?  
0.  No   ( Skip to 13 ) 
1. Yes           
11. In the past month was there ever 
no food to eat in your house 
because of lack of resources to 
get food? 
0.  No   ( Skip to 13 ) 
1. Yes                                
12. How often did this happen in the 
past month? 
4. Rarely (1-2 times) 
5. Sometimes (3-10 times) 
6. Often ( more than 10 times)  
13. In the past month did you or any 
household member go to sleep at 
night hungry because there was 
not enough food? 
0.  No   ( Skip to 15) 
1. Yes                                
14. How often did this happen in the 
past month? 
4. Rarely (1-2 times) 
5. Sometimes (3-10 times) 
6. Often ( more than 10 times)  
15. In the past month did you or any 
household member go a whole 
day and night without eating 
anything at all because there was 
not enough food? 
0.  No   ( Skip to 17 ) 
1. Yes                                
16. How often did this happen in the 
past month? 
4. Rarely (1-2 times) 
5. Sometimes (3-10 times) 
6. Often ( more than 10 times)  
17. How many times did you eat 
yesterday? 
( Coffee not counted) 
5. Once 
6. Twice 
7. Three times 
8. More than three times  
   
Part II Sun exposure behavior  
 
18. After giving birth to NAME did you 
stay inside your home for some time? 
 
( Asked only at 3 months ) 
0.  No  (Skip to 20) 
1. Yes     
19 If yes for how long did you stay inside 
your house? 
 
( Asked only at 3 months ) 
_________________ weeks  
20 Did you expose NAME to the sun?  
 
( Asked only at 3 months ) 
0.  No  (Skip to 23) 
1. Yes     
21. If yes how long after birth did you 
start exposing NAME to sunlight?   
 
( Asked only at 3 months ) 
_________days  
_________ Weeks  
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22. Do you put oil/butter on NAME skin 
when exposing to the sun? 
 
( Asked only at 3 months ) 
0.  No   
1. Yes     
23. Do you usually stay outside in the sun 
without an umbrella?  
0.  No  ( Skip to 26) 
1. Yes       
 
                         
24. If yes how often do you stay outside?  5. Once every two weeks  
6. Once per week 
7. Twice per week  
8. Every other day 
9. Daily 
Other (specify)_________________________ 
25. On a typical day for how long do you 
stay outside in the sun?  
_______________Minutes 
_______________ Hours  
26. How would you characterize your 
typical dress style when you stay 
work outside? 
 
( Interviewer: Show the respondent 
the clothing picture chart and record 
the appropriate letter) 
 
____________________ 
____________________ 
____________________ 
27. How would you characterize your 
typical dress style when you are at 
home?  
 
( Interviewer: use picture chart) 
___________________ 
____________________ 
____________________ 
28. How often do you wear sleeveless 
clothes? 
1. Once every two weeks  
2. Once per week 
3. Twice per week  
4. Every other day 
5. Daily 
Other (specify)_________________________ 
29. How often do you wear short sleeve 
clothes? 
1. Once every two weeks  
2. Once per week 
3. Twice per week  
4. Every other day 
5. Daily 
     Other (specify)_________________________ 
30. How often do you wear long sleeve 
clothes?  
1. Once every two weeks  
2. Once per week 
3. Twice per week  
4. Every other day 
5. Daily 
        Other (specify)_________________________ 
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31. Do you avoid staying out in the sun? 0.  No   
1. Yes                                
32. If yes why do you avoid sunlight? ____________________________________ 
____________________________________ 
 
33. Please describe all the outdoor activities you performed yesterday, including walking outside, from 
early in the morning until sundown?  
 
(Interviewer: Start with the first outdoor activity and list all the activities performed in the day. Use 
the clothing style picture chart to record the type of cloth worn during each activity. Probe for 
activities. ) 
 
Time of 
day 
Outdoor activity Time spent 
on activity 
Clothing worn 
during activity 
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Clothing style picture chart 
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